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Abstract 
 
 The Aryl hydrocarbon Receptor (AhR) is a ligand-activated transcription factor 
best known for its role in xenobiotic metabolism of environmental pollutants. Activation 
of the AhR by its prototypical ligand 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) leads to 
pronounced thymic atrophy and severe immunosuppression. Studies of AhR activation 
can have dual applications: to better understand AhR-mediated immunotoxicity and to 
harness its immunomodulatory effects for therapeutic use. Here, we first aimed to 
determine whether AhR-mediated thymic atrophy was ligand-dependent through the use 
of dietary and endogenously sourced ligands, indole-3-carbinol  (I3C) and 2-(19 H-
indole-39 -carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) respectively. We also 
aimed to identify key mediators of TCDD-induced thymic atrophy through the use of 
lineage-specific Cre-lox conditional knockout mice. We hypothesized that AhR 
activation induces thymic atrophy in a ligand-dependent manner and AhR expression 
within CD11c+ DCs is necessary for thymic atrophy by TCDD. In vivo exposure of ITE 
and I3C yielded dramatically different thymic outcomes with ITE resulting in severe 
thymic atrophy similar to TCDD while I3C did not induce atrophy. Through the use of 
Cre-Lox conditional knockout mice under lineage-specific promoters, we identified a 
requisite role for AhR activation in CD11c+ cells for TCDD-induced thymic atrophy.  
We next aimed to apply current understanding of AhR-mediated immune suppression in 
the development of a liposomal nanoparticle (LNP) delivery system for concentrated 
delivery of AhR-agonist, ITE, to dendritic cells. Dendritic cells are exquisitely sensitive 
to AhR activation and promote the generation of regulatory T cells.  ITE is a potent 
inducer of AhR activation; however, it is rapidly metabolized and systemic exposure to 
high doses can have undesirable effects. Therefore, we hypothesized that the generation 
and delivery of AhR agonist-loaded liposomal nanoparticles would activate the AhR in 
dendritic cells leading to a phenotype similar to TCDD, and result in cell-specific uptake 
when administered in vivo. LNP maintained high ITE entrapment, were of optimal size 
for dendritic cell uptake, induced AhR-responsive genes in vitro, and were preferentially 
taken up by splenic APCs. Together, this work furthers our understanding of AhR-
mediated thymic atrophy, and presents a novel AhR agonist delivery system for 
therapeutic application of the AhR.   
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CHAPTER 1: INTRODUCTION 
 
 This study describes the effects of aryl hydrocarbon receptor (AhR) activation on 
the thymus. Chapter 1 will: 1) introduce the AhR and its numerous ligands, 2) introduce 
the basic structure of the thymus and its role as a primary immune organ and 3) describe 
dendritic cells and their basic role within the immune system. 
 
THE ARYL HYDROCARBON RECEPTOR 
DISCOVERING THE AHR 
 
While multiple scientific advances coalesced into the discovery of the Aryl 
hydrocarbon Receptor (AhR), a common theme existed; namely the necessity to 
understand mechanisms of xenobiotic toxicity. Specifically, the discovery that 
polycyclic aromatic hydrocarbons (PAHs) appeared to induce their own metabolism 
drove the ultimate discovery of a receptor that could bind these compounds. First 
described by Allan Conney in the 1950’s, and originally termed the BP hydroxylase, 
due to its induced expression following exposure to benzo(a)pyrene (BaP), the 
receptor’s name was broadened to Aryl hydrocarbon Hydroxylase (AhH) in the 1970’s 
with the discovery that multiple PAHs were suitable ligands (Figure 1.1) (Okey et al. 
1979; Wright et al. 2017; Yao and Denison 1992). 
 Up until the late 1970’s, the AhR was still seen as a hydroxylase that was acted on 
by a receptor; the AhR itself being identified as a receptor had not yet come to fruition. A 
monumental contribution to AhR research came with the discovery that 2,3,7,8 
tetrachlorodibenzo-p-dioxin (TCDD), a halogenated aromatic hydrocarbon, could bind 
mammalian hepatocytes (Kouri et al. 1974). Following this discovery, TCDD was also 
determined to induce metabolism in tissues and systems previously found unable to do so 
with PAHs. These landmark studies enabled the ultimate identification of an “induction 
receptor” in 1976 by Poland, Glover, and Kende (Harper et al. 2006). Soon after, the 
receptor was termed Ah Receptor after Okey and Nebert documented its receptor-like 
activity (Wright et al. 2017; Yao and Denison 1992). Formally known as the Aryl 
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hydrocarbon Receptor, and with its prototypical ligand discovered, AhR research and its 
impacts across multiple disciplines, including immunology, were just beginning. 
 
 
Figure 1. 1 AhR Timeline of Discovery 
 
  
BP hydroxylase Discovered 
in hepatocytes (Conney, 
1950) 
1950 1970 
Renamed Aryl hydrocarbon 
Hydroxylase (AhH) after it was found 
to be induced by a broad range of 
chemicals (Nebert & Bausserman). 
AhH expression was necessary for 
toxic effects of  PAHs. 
1979 
Renamed Aryl 
hydrocarbon Receptor 
(AhR) after it was found to 
not only be induced, but 
to directly bind chemicals 
(Okey & Nebert) 
1984 
In Vivo experiment in mice and 
rats identified thymic atrophy 
as a key observation after AhR 
activation by PCBs. AhR is 
expressed for 2x as long in 
thymus as non-immune tissues 
Present 
 22 years of AhR research within 
the immune system 
Figure 1. 1 AhR Timeline of Discovery 
A brief timeline of key events that led to the discovery of the AhR and AhR research in 
the field of immunology. 
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AHR SIGNALING PATHWAYS 
 
 The AhR is a cytosolic, ligand-activated transcription factor in the basic helix-
loop-helix/Per-Arnt-Sim (bHLH/PAS) protein family. In mammals, the AhR is 
ubiquitous with temporal, cellular, and tissue-specific expression. Greatest AhR 
expression occurs in the liver, thymus, lung, kidney, spleen, and placenta (Harper et al. 
2006). Studies have shown that the AhR plays important roles beyond xenobiotic 
metabolism, including roles in hematopoiesis, immune system biology, neural 
differentiation, and liver formation (Wright et al. 2017). 
 In its inactive state, the AhR is found in the cytosol complexed to a host of 
chaperone proteins including XAP2, HSP90, and AIP. Upon ligand binding, a 
conformational change releases the chaperone proteins and exposes the nuclear 
localization sequence (Figure 1.2). The ligand:AhR is transported into the nucleus 
where it heterodimerizes with another bHLH/PAS protein, the Aryl hydrocarbon 
Receptor Nuclear Transporter (ARNT, HIF1β) (Yao and Denison 1992). 
Ligand:AhR/ARNT complexes specifically recognize and bind dioxin/xenobiotic 
responsive elements (DRE/XRE) in the promoter region of AhR-inducible genes 
(Dolwick et al. 1993). The mere presence of the DRE consensus sequence, 5'-
TNGCGTG-3', upstream of a gene can be used to determine whether the gene is AhR-
responsive, and most AhR-responsive genes have multiple DRE in the promoter region 
(Swanson et al. 1995). 
 The most common and consistent transcriptional target of the AhR canonical 
pathway following TCDD exposure is Cytochrome P450, family 1, subfamily A, 
polypeptide 1 (Cyp1a1), a phase I metabolizing enzyme. Within the promoter region of 
murine Cyp1a1, there are eight putative DREs and five of these are conserved between 
mouse, rat, and human (Li et al. 2014; Nukaya and Bradfield 2009). Therefore, 
measuring Cyp1a1 gene expression is both an accurate and a translational readout of 
AhR activation. Importantly, the AhR transcribes a host of other genes with cell/tissue 
specificity including indoleamine-2,3 dioxygenase 1 and 2 (IDO 1 and 2), isoforms of 
transforming growth factor beta (TGFβ), and retinaldehyde dehydrogenases (RALDH) 
(Vogel et al. 2008).  
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 Having discussed the AhR canonical pathway, it is necessary to briefly address 
the AhR non-canonical pathway, which is also shown in Figure 1.2. The AhR non-
canonical pathway occurs through alternative binding of nuclear AhR independent of 
ARNT and can result in expression of genes needed to maintain homeostasis (Wright 
et al. 2017). Less is currently understood regarding the interactions and implications of 
the non-canonical pathway. 
 
Figure 1. 2 AhR signaling pathways. 
 
  
Figure 1.2 AhR signaling pathways.  
A diagram of protein interactions involved in the AhR canonical and non-canonical 
signaling pathways.  In the canonical AhR signaling pathway, a ligand diffuses into the 
cell and binds cytosolic AhR complex, which triggers dissociation of chaperone proteins. 
The ligand-bound AhR translocates to the nucleus where it binds ARNT enabling binding 
to canonical DREs and triggering transcription of the AhR gene battery. In the non-
canonical signaling pathway, the ligand-bound, nuclear AhR binds proteins independent 
of ARNT. RelB in the nucleus thereby allows binding to NF-kB response elements. 
(Wright et al. 2017) 
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AHR ALLELES  
 
 In the early years of AhR research, there were conflicting results regarding 
protein and ligand binding, which can now be attributed to the use of mouse strains with 
different AhR alleles. These alleles include AhRb-1, AhRb-2, AhRb-3, and AhRd (Smith et 
al. 2018). C57Bl/6 mice carry the best-studied allele: AhRb-1, which readily binds TCDD 
with high affinity. DBA/J mice, however, carry the AhRd allele with a 10x lower binding 
affinity for TCDD due to an alanine375 to valine substitution in the ligand-binding domain 
(Ema et al. 1994). Additionally, the AhR demonstrates both basal and inducible 
expression that is dependent on tissue and cell type. In mammals, organs known to have 
the highest basal AhR expression levels include the liver, lung, kidney, spleen, placenta, 
and thymus (Harper et al. 2006). Within the immune system, AhR is expressed basally by 
a majority of cells types, and increased AhR expression occurs with exposure to 
xenobiotics, mitogens, antigens, and cytokines (Pohjanvirta 2011) 
  Importantly, AhRb-1 mouse models have so far been the predominant source for 
our current understanding of the AhR, but there are differences between the AhRb-1 allele 
expressed in mice and the AhR expressed in most humans, which share 85% sequence 
homology. The human AhR binds to TCDD more similar to the AhRd mouse allele with 
~10x lower affinity than murine AhRb-1. Interestingly, human AhR has a similar mutation 
to murine AhRd with an amino acid substitution in the ligand-binding domain, and some 
research suggests that the human AhR may bind endogenous compounds with greater 
affinity than exogenous compounds (Hubbard et al. 2016).   
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AHR LIGANDS 
 
 While TCDD is the prototypical AhR ligand, due to its high binding affinity, 
numerous compounds are known to bind and activate the AhR. AhR ligand interactions 
that are best understood involve planar, hydrophobic, highly toxic environmental 
compounds within the halogenated aromatic hydrocarbons (HAHs) and polycyclic 
aromatic hydrocarbons (PAHs); however, the increased interest in AhR in multiple fields 
has resulted in a continual identification of AhR ligands beyond the classical, exogenous 
HAHs.   
 Classical ligands do not vary far from the prototypical AhR ligand, TCDD, and 
generally take planar conformations with multiple benzene rings and act as AhR agonists. 
Importantly, a broad range of non-classical ligands, those that vary substantially from 
TCDD, can readily bind the AhR (Figure 1.3)(Pohjanvirta 2011). Notably, compounds 
with demonstrated antagonistic properties also directly bind the AhR, and can result in 
ligand-selective antagonism. Notably, 2-methyl-2H-pyrazole-3-carboxylic acid (2-
methyl-4-o-tolylazo-phenyl)-amide (CH223191) can block binding of TCDD and other 
halogenated aromatic hydrocarbons (HAH), without blocking binding of non-HAH 
ligands (Pohjanvirta 2011). 
 While TCDD is an exogenous compound, endogenous compounds have also been 
identified. The earliest and arguably most notable is 2-(1′H-indole-3′-carbonyl)-thiazole-
4-carboxylic acid methyl ester (ITE), which was isolated from porcine lungs in 2002, and 
found to bind AhRb with moderate affinity (3nM ITE vs .27nM TCDD) (Song et al. 
2002). The identification of an endogenous ligand was a pivotal finding as the AhR is a 
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highly conserved protein and its roles in xenobiotic metabolism and immune modulation 
are likely more recent adaptive functions.  
 Diet is a prominent source of AhR ligands—from both bioaccumulation of TCDD 
in fatty tissue of animals and from plant-derived ligands such as Indole-3-carbinol (I3C). 
In fact, one study analyzing body burden of TCDD-equivalents (TEQs) found plant-based 
dietary ligands to be a greater contributor (96% of TEQ) than TCDD to total body burden 
in humans (Connor and Finley 2003). Notably, ligand affinity, an important factor, was 
not addressed in this analysis, but it highlights the need to study a variety of ligands 
beyond TCDD, including those from dietary sources.    
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Figure 1. 3 A representative panel of AhR ligands 
 
 
Figure 1.3 A Representative Panel of AhR ligands.  
A panel of known AhR ligands intended to show their variation and similarity 
(Denison and Nagy 2003).  
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AHR-INDUCED IMMUNOSUPPRESSION 
 
In 1984, thymic expression of the AhR in Sprague-Dawley rats was determined to 
occur at high levels for twice as long (42 days vs. 21 days) after parturition as compared 
to non-immune tissues such as liver and lungs (Nikolaidis et al. 1988). These 
observations led to further investigation of AhR activity in immune organs, and the 
discovery that AhR activation had adverse effects on thymic function. In 1985, PCBs 
acting through the AhR were found to cause severe thymic atrophy and humoral immune 
suppression (Hanieh 2014). The succession of rapid discoveries throughout the 1980s 
broadened the expanse of AhR-mediated suppression within the immune system to 
include: reduction in splenic lymphocyte number and function in mice, reduced humoral 
antibody response in mice and rats, and overall reduction in ability of mice to fight 
certain infections (Goudot et al. 2017).  
With a potential link made between the AhR and observed suppression of the 
immune system, immunologists entered into a field, which to this point had 
predominantly been pioneered by toxicologists and biochemists. The interweaving of 
discoveries from these disciplines has both expanded our understanding of the AhR 
signaling pathway and of the immense complexity of the innate and adaptive immune 
responses.  
Innate immune cells strongly vary in AhR expression (Figure 1.4), ranging from 
high, constitutive expression, to low, conservatively inducible expression. The outcome 
of AhR activation on promotion or regulation of immune responses also appears to vary 
by cell type and maturation phase. Interestingly, both inflammatory and regulatory genes 
have an abundance of AhR responsive elements within their promoter regions, and it has 
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been shown that cross-talk between AhR and NF-B results in multiple pro-inflammatory 
signals (Goudot et al. 2017). Neutrophils, and most granulocytes are not thought to 
express the AhR at significant levels and appear to be predominantly influenced by AhR 
activation through an indirect mechanism.  
 Antigen presenting cells, macrophages and dendritic cells, constitutively express 
the AhR at relatively high levels and show further AhR expression upon activation and 
maturation (Kreitinger et al. 2016). It has also been shown in vitro that AhR activation in 
monocytes selectively promotes differentiation of murine monocyte-derived DCs through 
induction of BLIMP-1 (Goudot et al. 2017), while impairing differentiation of monocyte-
derived Macs. Additionally, AhR deficiency correlated with a reduced frequency of 
monocyte-derived DCs in vivo (Goudot et al. 2017). Dendritic cells are highly responsive 
to AhR activation and demonstrate AhR-mediated alterations to maturation, protein 
expression, and gene induction. Specifically, AhR activation results in an increase in 
immature dendritic cells as marked by moderate CD11c and MHII expression. AhR-
activated dendritic cells show increased frequency and density of co-stimulatory 
molecules as well as increased expression of regulatory genes, including Indoleamine 
2,3-dioxygenase-1,-2 (IDO-1,-2) and transforming growth factor beta (TGF). AhR-
induced regulatory DCs are potent inducers of Foxp3+ regulatory T cells, while direct 
exposure of naïve T cells to AhR activation appears to induce non-Foxp3+ Tregs 
(Bankoti et al. 2010c; Benson and Shepherd 2011b; Gagliani et al. 2015; Qiu et al. 2012).  
 Natural killer cells, which are thought to have basal expression of AhR, are 
reported to have reduced bacterial clearance and tumor cell recognition capacity in AhR-/- 
mice. These studies also suggest that NK cells are, in part, directly affected by AhR 
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activation with a modest immune enhancement function (Winans et al. 2015). 
Conversely, there are also reports showing AhR-mediated immunosuppressive NK cell 
function, which suggests that additional environmental, or maturational components may 
be involved in AhR-mediated effects on NK cells (Kreitinger et al. 2016). 
 Innate lymphoid cells (ILCs), which play an important role in mucosal immunity, 
were shown to have compromised bacterial clearance through reduced IL-22 expression 
when ILCs lacked AhR (Pearse 2006). While AhR research in ILCs is relatively minimal, 
current literature suggests AhR activation in ILC subsets may be necessary for infection 
clearance within mucosa. AhR impacts CD4+ T cell subsets, both directly and indirectly, 
to different ends; variation in AhR expression levels is a probable explanation. Th1 and 
Th2 cells, which are thought to have minimal AhR expression, show AhR-mediated 
immune deviation. Specifically, Th1 cells become the dominant subset over Th2 cells 
through GATA binding protein-3 (GATA-3) inhibition in naïve T cells (Kreitinger et al. 
2016). Th17 cells, which are known to express high levels of AhR, are shown to undergo 
rapid expansion upon direct AhR activation. Interestingly, with influences from AhR 
activation and subsequent TGF signaling, new research shows that inflammatory Th17 
cells can undergo transdifferentiation to Tr1 cells, a Foxp3- regulatory T cell subset 
(Pearse 2006). CD4+ Foxp3+ regulatory T cells (Tregs) moderately express the AhR, and 
AhR activation in DCs significantly increases regulatory T cell frequency and effector 
functions indirectly (Kreitinger et al. 2016).  Within CD8+ T cells, recent discoveries 
have found that AhR activation by xenobiotics during development has long-lasting 
effects on CD8+ frequencies through an epigenetic mechanism, ultimately reducing 
antiviral capacities (Pearse 2006).  At this time, AhR expression in B cells is not well 
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understood. It has been documented by numerous studies that AhR activation by 
xenobiotics reduces antibody production and overall humoral immunity; however, it has 
not been determined whether this reduction in humoral immunity is due to direct AhR 
activation in B cells. Altered antibody production has been associated with both CD4+ T 
cell and DC AhR activation.  
 
Figure 1. 4 AhR Expression in Immune Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 AhR Expression in Immune Cells. 
AhR expression (x-axis) and outcomes of AhR activation (y-axis) by immune cell type. 
Importantly, AhR expression by cell type is based on mRNA and not protein expression. 
(Kreitinger et al. 2016) 
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THE THYMUS 
 
A PRIMARY IMMUNE ORGAN  
 
 The thymus is a multi-lobed primary immune organ that rests directly above the 
heart. The thymus and bone marrow compose the mammalian primary immune organs 
with important roles in development, differentiation, and education of competent immune 
cells. From primary immune organs, immature immune cells seed most tissues of the 
periphery including secondary lymphoid tissues such as the spleen and lymph nodes, sites 
of mucosa, and skin to form the innate and adaptive immune systems. 
 
STRUCTURE AND ORGANIZATION 
 
 Both hematopoietic and non-hematopoietic cells constitute the thymus. Stromal 
elements including epithelial cells and fibroblasts, as well as dendritic cells, organize the 
thymus into two functionally distinct microenvironments: cortex and medulla (Figure 
1.5). The cortex, which is the more outer tissue of the thymus, has a high cellular density 
predominantly composed of small, immature thymocytes (Murphy and Weaver 2016; 
Pearse 2006). The cortex is an area of rapid cell division and cell death with lymphoblasts 
undergoing mitosis and large numbers of thymocytes undergoing apoptosis. There are 
relatively low numbers of epithelial cells in the cortex and relatively high numbers of 
macrophages in order to phagocytize apoptotic bodies (Murphy and Weaver 2016; Pearse 
2006). 
 The medulla is the more central portion of the thymus and has a lower cell density 
than the cortex (Murphy and Weaver 2016; Pearse 2006). Cells that have passed the first 
stage of selection, discussed in detail below, will migrate to the medulla where they 
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interact with dendritic cells and medullary thymic epithelial cells (mTECs) and undergo 
the second stage of selection. Cells undergo turnover much less rapidly than in the cortex 
and will leave the medulla as fully functional naïve T cells.   
 
Figure 1. 5 Thymus Organization. 
 
 
Figure 1.5 Thymus Organization.  
A diagram of thymic organization and thymocyte development. (Blackburn and Manley 2004) 
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T CELL SELECTION 
 
 T cells, a key component of adaptive immune responses, are produced in the 
thymus. Once in the thymus, CD3-, T cell Receptor- (TCR), CD4-/CD8- (double-
negative, DN) lymphoid precursors interact with thymic stroma and undergo necessary 
commitment to either 
the αβ or λδ T cell lineage through TCR gene rearrangement.  αβ T cells, which compose 
a majority of thymocytes, undergo strict selection events that can be tracked by surface 
protein expression of CD4 and CD8 co-receptors (Figure 1.6) (Savino 2006).  
 First, CD4+ CD8+ thymocytes (double-positive, DP), which make up a majority 
of thymocytes, undergo positive selection in the cortex where only cells with TCRs that 
can recognize self-peptide:self-MHC presented by cortical epithelial cells (cTECs) will 
survive. Most cells do not express receptors that can recognize self-peptide complexes 
and therefore most DP thymocytes die. Cells that have successfully passed positive 
selection will undergo negative selection, which occurs in the medulla and is facilitated 
by medullary epithelial cells (mTECs) and dendritic cells (DCs), to ensure that they do 
not recognize self antigens too strongly. A small niche of self-recognizing thymocytes is 
not negatively selected, but instead is driven toward a regulatory phenotype leading to 
thymic Tregs.  
 Cells that fail negative selection undergo programmed cell death, and are 
predisposed to Bim-mediated apoptosis. For the ~2% of cells that successfully navigate 
positive and negative selection, down-regulation of either CD4 or CD8 corresponds with 
the cell’s ability to recognize extracellular antigen bound to MHC II or self-peptides 
bound to MHCI, respectively (Murphy and Weaver 2016). These successfully 
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recombined CD4+ or CD8+ single positive (SP) naïve T cells will then leave the thymus 
to seed the periphery. Overall, these critical selection events ensure only centrally tolerant 
and functional, immature T cells develop. Unlike αβ T cells, γδ T cells are a distinct but 
minor lineage that does not undergo positive and negative selection. Some γδ T cell 
receptors may recognize antigen directly, in a way similar to antibodies, and are not 
restricted to antigen presented on Major Histocompatibility Complexes (MHC) like αβ T 
cells. γδ T cells are currently not well studied, but it is understood that γδ T cells leave 
the thymus to seed peripheral tissues, such as the dermis, in waves or bursts that 
correspond with development (Murphy and Weaver 2016). 
Figure 1. 6 Thymocyte Maturation. 
  
Figure 1.6 Thymocyte Maturation.  
Diagram of thymic selection where thymocytes transition from CD4/CD8 double 
negative (DN) to double positive (DP) to single positive (SP) (Savino et. al, 2006). 
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THYMIC ATROPHY  
 
 Thymic atrophy is the severe shrinking of thymic tissue and occurs for a variety 
of reasons. Age-related thymic atrophy is considered a natural process where the thymus 
begins a slow, steady decline after adolescence. Numerous studies suggest that age-
related thymic atrophy is due to alterations in the stromal compartment, predominantly 
epithelial cells, and corresponds with reduced Foxn1, a transcriptional regulator 
necessary for thymic epithelial cell (TEC) development (Cepeda and Griffith 2017; 
Lepletier et al. 2015; Masters et al. 2017). Interestingly, during age-related thymic 
atrophy, thymic tissue is replaced by an increased deposition of adipose tissue (Cepeda 
and Griffith 2017). 
 Age-related thymic atrophy decreases thymic output of naïve T cells, which leads 
to a narrowing of peripheral TCR repertoires (Murray et al. 2003; Surh and Sprent 2000). 
As fewer naïve T cells are produced within the aged thymus, the periphery continues to 
expand peripheral T cells, which leads to a skewed ratio of naive T cells to memory T 
cells. Consequently, the reduced output of naïve T cells and corresponding expansion of 
peripheral T cells leads to a systemic reduction in the diversity of TCR repertoires over 
time.  
 Notably, T cell output by an aged thymus is not completely inhibited, but naïve T 
cells that are successfully formed exhibit a high potential for senescence, marked by 
increased CD57 expression, and show a limited response upon exposure to antigenic 
stimuli (Mo et al. 2003). Additional phenotypic differences in naïve T cells generated by 
aged-thymi include reduced CD62L, a lymph node-homing protein and the chemokine 
CCR7, which suggests these T cells may not properly mobilize to relevant lymphoid 
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tissues (Haynes and Swain 2006). Together, these alterations would lead to defective 
responses to primary antigen exposures, such as new pathogens or vaccinations, as well 
as novel, endogenous tumor antigens. 
  Conversely, aged-thymi are also associated with autoimmune diseases that 
develop in geriatric patients (Prelog 2006). As previously discussed, the thymus strictly 
selects against self-reactive T cells prior to their entry into the periphery, a process 
largely controlled by thymic DCs and TECs; however, these stromal cell populations 
undergo substantial loss during age-induced atrophy, resulting in an increase in auto-
reactive T cell escape, and ultimately a weakening of central tolerance corresponding 
with chronic inflammation (Coder et al. 2015). 
 Importantly, aging is not the only factor able to induce thymic atrophy. In fact, 
periodic and stochastic thymic atrophy can occur from infection, pharmaceuticals, 
including chemotherapies and high-dose antibiotics, some cancers and tumors, 
pregnancy, and exposure to toxicants such as TCDD (Cepeda and Griffith 2017). These 
forms of thymic atrophy appear to differ from, and may exacerbate, age-related thymic 
atrophy in that they are often transient with partial recovery/regeneration occurring once 
the contributing factor or insult is removed.   
 
AHR AND THYMUS 
 
  The thymus expresses high levels of AhR (Carlstedt-Duke 1979) and thymic 
atrophy by TCDD was first noted in a 1970’s study where multiple laboratory rodent 
species were exposed to TCDD via gastric intubation (Harris et al. 1973; Poland and 
Glover 1975). It was a key study in the 1980’s that connected AhR activation to the 
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drastic alterations of a primary immune organ, becoming a key turning point in AhR 
research that peaked the interest of immunotoxicologists. Additionally, thymic atrophy 
and nutmeg liver became hallmark signs of exposure to exogenous AhR ligands, and it 
was long thought that the profound suppression of T cell-mediated immune responses 
was in part due to disrupted T cell development within the atrophied thymus.  
 Immunological studies assessed alterations to thymic cells in adult mice, as well 
as in utero and in vitro fetal thymic cultures (Esser and Welzel 1993; Holladay et al. 
1991; Lutz et al. 1998; Poland and Glover 1975). These studies determined that the 
thymus was directly affected by TCDD, predominantly through a significant depletion of 
CD4+CD8+ double positive (DP) thymocytes (Esser and Welzel 1993; Holladay et al. 
1991; Silverstone et al. 1994b). This loss of DP thymocytes was believed, at the time, to 
underlie the profound suppression of peripheral T cell responses following exposure to 
TCDD and dioxin-like compounds.  
 Interestingly, while TCDD-induced thymic atrophy is largely due to a loss of DP 
thymocytes, developing thymocytes have relatively low basal AhR expression as 
measured through mRNA, suggesting the DP loss is an indirect effect of AhR activation 
(Figure 1.7). Importantly, hematopoietic and non-hematopoietic cells constitute the 
thymus, and thymic precursors seed the thymus from bone marrow. Studies suggested 
that TCDD affected thymocytes from bone marrow (Silverstone et al. 1994b); however, 
the contributions of AhR expression within hematopoietic and non-hematopoietic cells 
remained a key question. 
 Staples et al. (1998) performed bone marrow chimera studies where they 
irradiated AhR+ mice and AhR-/- mice to deplete bone marrow derived cells. Chimeras 
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were created with AhR+ mice receiving AhR-/- bone marrow, and AhR-/- mice receiving 
AhR+ bone marrow prior to TCDD exposure. Interestingly, only mice that had AhR 
expression in bone marrow underwent thymic atrophy. This key finding determined that 
AhR expression in hematopoietic cells was necessary to induce thymic atrophy following 
TCDD exposure. Notably, the hematopoietic compartment is highly heterogeneous 
(Figure 1.7) and a key question that has remained unanswered since these early studies is 
whether AhR expression within specific cell types of the hematopoietic compartment is 
responsible for thymic atrophy.  
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Figure 1. 7 AhR Expression within the hematopoietic compartment. 
 
 
  
Figure 1.7. A diagram of AhR expression in cells of the hematopoietic compartment 
(Esser and Rannug 2015) . Shades of blue represent AhR expression potential 
consolidated from studies using qPCR and Western blot analysis. Plus signs (+)denote 
cells where AhR activation has been described to alter the function of the cell. Asterisks 
(*) denote cells in which AhR is suggested to play a role in lineage-specific 
differentiation. 
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DENDRITIC CELLS 
 
PROFESSIONAL ANTIGEN PRESENTING CELLS 
 
 Just as research in the 1970’s was leading to the discovery of the AhR, research 
by Ralph Steinman during this time was leading to the identification of dendritic cells 
(DCs) (Merad et al. 2013). DCs are described as professional antigen-presenting cells for 
their ability to phagocytize, internally process, and present antigen bound to surface 
proteins called major histocompatibility complexes (MHC). In mice, MHCI are loaded 
with short peptides derived from intracellular proteins while MHCII are able to 
accommodate slightly longer peptides from extracellular proteins. These antigen:MHC 
complexes act as a key form of communication between DCs and T cells.  
 According to the three-signal hypothesis (Figure 1.8), DCs employ cognate and 
soluble interactions to orchestrate three key signals when communicating with T cells 
(Kambayashi and Laufer 2014). First, peptide-loaded MHC on the surface of DCs 
interact with T cell receptor (TCR) complexes. Second, surface proteins on the DCs 
including CD80 and CD86 or CD40, interact with CD28 or CD40L on the T cell to 
provide co-stimulatory signals. Last, cytokines produced by dendritic cells act as soluble 
instructors to influence the fate and response of antigen-specific T cells. Together, these 
interactions result in both positive and negative signaling cascades in the T cells that 
ultimately result in differentiation, cellular proliferation, and/or activation-induced cell 
death. This emphasizes the critical role that DCs play in T-cell differentiation, 
homeostasis, activation, acquisition of effector functions, and apoptosis.  
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 Together, T cells and dendritic cells interact with B cells to promote antigen-
specific antibody responses through B cell proliferation and isotype (class) switching.  
While B cells can recognize soluble antigens independently of dendritic cells, the 
presentation of antigen by dendritic cells is crucial for the development of efficient 
humoral responses. AhR activation has long been shown to disrupt humoral immune 
responses, predominantly through reduced IgG expression. Interestingly, IgA expression 
is enhanced with AhR activation and some of our work that has been previously 
presented, but not to be discussed at length in this dissertation, suggests the effects on Ig 
secretion is, in-part, due to AhR activation within dendritic cells. 
Figure 1. 8 The Three-signal Hypothesis 
Figure 1. 8 The Three-signal Hypothesis. Within this hypothesis, signal 1 is formed by the 
cognate interactions of MHC on dendritic cells with TCR and TCR co-receptor on T cells. Signal 
2 is also a cognate interaction between co-stimulatory molecules including CD40-CD40L, 
CD80/86-CD28/CD3, while signal three includes soluble factors including cytokines such as 
inflammatory IL-12 or inhibitory IL-10. (Kambayashi and Laufer 2014) 
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DIVERGENT FUNCTIONS OF DCS 
  
 DCs can acquire diverse activation, maturation, and functional states that 
correspond with a dichotomy in immune responses (Figure 1.9). Stimulatory, or 
inflammatory DCs, release inflammatory cytokines including IFNγ, TNFα, and IL-6 to 
drive inflammatory T cell responses required for protection against pathogens and 
tumors. However, aberrant stimulatory DC presence can promote the development of 
autoimmune pathologies. Conversely, DCs can adopt a regulatory phenotype through 
signals within their microenvironment, such as TGFβ, IL-10, or compounds that bind and 
activate the AhR. Regulatory DCs play an important role in organ homeostasis through 
inhibition of T cell activation and promotion of regulatory T cell differentiation and/or 
maintenance and provide a promising potential route for therapeutic immune suppression. 
  
Figure 1. 9 Divergent DC Functions 
 
Figure 1.9 Divergent DC Functions 
Diagram depicting signal integration in immature DCs and subsequent stimulatory 
versus regulatory DC outcomes. Schmidt et al., 2012.  Frontiers in Immunol. 3 
(274); 1-17. 
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DCs IN THE THYMUS 
 
 DCs play another key role in the formation of the adaptive immune system 
through interactions with developing thymocytes in the thymus.  In mice, hematopoietic 
DCs, which share a common lineage marker, CD11c, can be divided into numerous 
subsets dependent on tissue and location. Within the thymus, DC populations consist of 
conventional DCs (cDCs) and plasmacytoid DCs (pDCs). Studies using parabiotic mice 
congenic for CD45.1 or CD45.2 established that thymic cDCs can be subdivided into two 
populations with different developmental origins. Resident, thymus-derived cDCs 
(cDC1), identified by expression of CD11c+ CD8α+ Sirpα-, arise from precursors within 
the thymus. Migratory cDCs (cDC2) identified by expression of CD11c+CD8α- Sirpα+, 
are present in circulation prior to seeding the thymus (Proietto et al. 2008a).  
 cDC1 and cDC2 were shown to be equally competent at performing negative 
selection of DP thymocytes while plasmacytoid DCs were not as effective at negative 
selection (Atibalentja et al. 2011). cDC2 may participate in thymic selection through 
presentation of processed antigen taken up while in the periphery, or by transfer of 
peptides from cDC1 and thymic epithelial cells once they have migrated into the thymus 
from the periphery (Allan et al. 2006; Atibalentja et al. 2011; Knight et al. 1998). 
Additionally, both thymic cDC1s and sDC2s show an ability to induce CD4+ CD25+ 
Foxp3+ regulatory T cells (Tregs) from naïve T cells in culture (Proietto et al. 2008a). 
 
AhR AND DC 
 
 Of immune cells with AhR mRNA levels currently characterized, DCs are 
considered to be one of the highest expressers (Figure 1.4 and 1.7) (Esser and Rannug 
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2015). AhR activation in DCs by TCDD is associated with alterations to antigen 
presentation and costimulatory molecules, including ICAM-1, CD24, CD86, and CD40 
(Vorderstrasse and Kerkvliet 2001). Steady-state DCs, a term for DCs cultured in vitro 
with granulocyte macrophage-colony stimulating factor (GM-CSF) instead of Flt3-
ligand, showed reduced MHC class II, CD86, CD80, and CD54 and were associated with 
increased generation of CD4+ Foxp3+ Tregs in vitro (Simones and Shepherd 2011) .  
 Dietary compounds, indole-3-carbinol (I3C) and indirubin-3-oxime (IO) were 
found to reduce expression of CD40, CD54, and CD11c while increasing MHCII and 
CD80 on murine CD11c+ DCs in vitro. These dietary compounds also altered gene 
expression with increased mRNA for genes, including ALDH1A, IDO, and TGFβ. These 
genes code for proteins that are able to metabolize available tryptophan, reducing its 
availability for proliferating immune cells and initiating class switching of antibody 
isotypes, and are implicated in the regulatory DC phenotype and the generation of 
regulatory cells (Quintana et al. 2010c). These dietary compounds also reduced DC 
production of pro-inflammatory cytokines: tumor necrosis factor alpha (TNFα), IL-1β, 
IL-12, and IL-6 while increasing IL-10 protein levels (Benson and Shepherd 2011b). 
Importantly, unlike TCDD, the effects of dietary ligands were partially mediated by the 
AhR (Benson and Shepherd 2011b) . 
 While these effects of AhR activation were observed in steady-state DCs 
(Simones and Shepherd 2011), it was also necessary to determine whether these effects 
could occur in DCs within an inflammatory environment. In vitro generation of 
inflammatory DCs exposed to LPS or CpG showed marked reduction in inflammatory 
signaling when exposed to TCDD (Bankoti et al. 2010a; Bankoti et al. 2010b).  
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Importantly, AhR expression and consequences of AhR activation in murine DCs is 
highly translational as AhR expression occurs at high levels in human DCs and human 
DCs exposed to AhR agonists lead to suppressed T cell responses through reduced Th1 
and Th17 polarization (Platzer et al. 2009; Wang et al. 2014). 
 DCs are an immune cell population that is highly susceptible to AhR activation by 
an array of ligands and are present in most tissues. Considering the important role of DCs 
in thymocyte selection and the numerous, broad effects of AhR activation in DCs, the 
consequences of AhR activation on DCs in thymus and their potential role in AhR-
induced thymic atrophy is of key interest. 
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SPECIFIC AIMS 
 
AHR-MEDIATED THYMIC ATROPHY  
 
 Within the thymus, AhR activation by TCDD results in a dramatic loss of 
developing thymocytes, which is associated with reduced frequency of double positive 
(DP, CD4+CD8+) thymocytes, and relative increases in the frequency of double negative 
(DN, CD4-CD8-) and single positive (CD4+ SP and CD8+ SP) thymocytes (Kamath et al. 
1998; Kamath et al. 1997; Lundberg et al. 1990).  Multiple mechanisms may contribute 
to the loss of thymocytes, including reduced proliferation of DN precursor thymocytes 
(Lai et al. 1994), enhanced apoptosis via Fas:FasL interactions at the DP stage (Camacho 
et al. 2005b), and more rapid emigration of thymocytes to the periphery (Temchura et al. 
2005). It is of keen interest to determine whether these effects are due to AhR activation 
within the developing thymocytes and/or in other thymic cell populations of the thymus. 
Studies using murine bone marrow chimeras showed that thymic atrophy by TCDD is 
dependent on AhR activation within the hematopoietic compartment (Staples et al. 1998); 
however, the hematopoietic compartment is highly heterogeneous, and the specific 
immune cell contributor(s) have not yet been identified. Preliminary data from our 
laboratory suggest that AhR activation in CD11c+ cells, a lineage marker for DCs, plays 
a requisite role in TCDD-induced thymic atrophy. To corroborate these initial findings, it 
is necessary to evaluate the role of AhR expression in other key lineages of the 
hematopoietic compartment.  
 Additionally, while TCDD is the prototypical AhR ligand due to its demonstrated 
high binding affinity, the AhR is a highly promiscuous receptor known to bind an array 
of compounds (Pohjanvirta 2011). Dietary compounds such as indole-3-carbinol (I3C) 
and endogenous compounds such as 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid 
methyl ester (ITE) can bind and activate the AhR, and ligand-specific effects are known 
to occur (Pohjanvirta 2011; Song et al. 2002). Of late, there has been substantial interest 
in harnessing AhR-mediated immunosuppression for treatment of inflammatory diseases 
(Quintana et al. 2010a); however, TCDD is highly toxic and natural AhR ligands are 
gaining traction as promising alternatives. Therefore, it is also of great interest and 
relevance to assess thymic atrophy in response to AhR ligands beyond TCDD. Thus, the 
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first aim of this dissertation was to evaluate thymic atrophy by a select panel of ligands 
and determine the role of AhR activation within hematopoietic cell lineages for TCDD-
mediated thymic atrophy.  
 
AGONIST-LOADED LIPOSOMAL NANOPARTICLES FOR THERAPEUTIC 
ACTIVATION OF THE AHR. 
 
 AhR activation is a potent immune-modulator and shows immense promise in the 
treatment of autoimmune diseases (Quintana et al. 2010a). However, it is well 
documented that the effects of AhR activation during an immune response vary based on 
the target cell (Esser and Rannug 2015; Kreitinger et al. 2016; Stockinger et al. 2014) and 
that AhR activation can result in drastically different outcomes, from increasing 
inflammatory responses to promoting immune regulation or tolerance (Lee et al. 2015b). 
Harnessing the immunosuppressive effects of AhR activation within specific immune cell 
populations through a targeted delivery system would enable treatment of immune and 
inflammatory diseases while circumventing the deleterious effects of systemic AhR 
activation and subsequent non-specific immune modulation. Specifically, DCs 
constitutively express AhR at high levels, are keenly sensitive to AhR expression by 
multiple ligands, and adopt a regulatory phenotype that directly induces Tregs, making 
them an attractive target for AhR agonists (Quintana et al. 2010c; Simones and Shepherd 
2011). 
 While AhR activation in DCs holds immense promise for treatment of 
autoimmune and inflammatory diseases, TCDD is highly toxic and exhibits a long half-
life in humans; properties that make TCDD undesirable for pharmaceutical use (Harris et 
al. 1973; Kerkvliet 2012; Miniero et al. 2001). Natural AhR ligands, such as ITE, are 
more desirable for therapeutic purposes; however, natural ligands are more rapidly 
metabolized than TCDD and thus require higher and more frequent doses (Abron et al. 
2018; Benson and Shepherd 2011b; Song et al. 2002). Importantly, packaging 
compounds within nanoparticles has been shown to improve drug solubility and potency, 
reduce off-target effects, and protect the drugs against metabolic degradation 
(Akbarzadeh et al. 2013). Liposomal nanoparticles (LNPs) are biodegradable and 
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biocompatible delivery systems for enhanced therapeutic benefits, both in vitro and in 
vivo, and are considered to be the most successful drug-carrier system to date (Bozzuto 
and Molinari 2015). Taken together, it is of keen interest to develop ITE-loaded LNPs 
and to evaluate ITE-loaded LNPs for biological effects in dendritic cells. Thus, the 
second aim of this dissertation was to generate ITE-loaded LNP, to assess LNP uptake 
efficiency, cytotoxicity, and phenotypic changes in bone marrow derived dendritic cells in 
vitro, and to evaluate biodistribution of LNPs in vivo. 
 
Specific Aim 1: Evaluate thymic atrophy by a select panel of ligands and determine 
the requirement of AhR activation within hematopoietic cell lineages for TCDD-
mediated thymic atrophy.  
 
 Hypothesis: AhR activation induces thymic atrophy in a ligand-dependent 
 manner and AhR expression within CD11c+ DCs is necessary for thymic atrophy 
 by TCDD. 
 
Specific Aim 2:  Generate ITE-loaded LNP, assess LNP uptake efficiency, 
cytotoxicity, and phenotypic changes in bone marrow derived dendritic cells 
(BMDCs) in vitro, and evaluate biodistribution of LNP in vivo. 
 
 Hypothesis: We hypothesize that delivery of AhR agonist-loaded liposomal 
 nanoparticles will activate the AhR leading to a BMDC phenotype similar to 
 TCDD, and result in cell-specific uptake in vivo. 
 
 
 
 
 
 
 
 
 
 
 31
REFERENCES 
 
 
Abron JD, Singh NP, Mishra MK, et al. (2018) An endogenous aryl hydrocarbon 
receptor (AhR) ligand, ITE induces regulatory T cells (Tregs) and ameliorates 
experimental colitis. Am J Physiol Gastrointest Liver Physiol 
doi:10.1152/ajpgi.00413.2017 
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013) Liposome: classification, 
preparation, and applications. Nanoscale research letters 8(1):102  
Allan RS, Waithman J, Bedoui S, et al. (2006) Migratory dendritic cells transfer 
antigen to a lymph node-resident dendritic cell population for efficient CTL 
priming. Immunity 25(1):153-162  
Atibalentja DF, Murphy KM, Unanue ER (2011) Functional redundancy between 
thymic CD8α+ and Sirpα+ conventional dendritic cells in presentation of 
blood-derived lysozyme by MHC class II proteins. The Journal of Immunology 
186(3):1421-1431  
Bankoti J, Burnett A, Navarro S, Miller AK, Rase B, Shepherd DM (2010a) Effects of 
TCDD on the fate of naive dendritic cells. Toxicol Sci 115(2):422-34 
doi:10.1093/toxsci/kfq063 
Bankoti J, Rase B, Simones T, Shepherd DM (2010b) Functional and phenotypic 
effects of AhR activation in inflammatory dendritic cells. Toxicol Appl 
Pharmacol 246(1-2):18-28 doi:10.1016/j.taap.2010.03.013 
Bankoti J, Rase B, Simones T, Shepherd DM (2010c) Functional and phenotypic 
effects of AhR activation in inflammatory dendritic cells. Toxicology and 
applied pharmacology 246(1):18-28  
Benson JM, Shepherd DM (2011b) Dietary ligands of the aryl hydrocarbon receptor 
induce anti-inflammatory and immunoregulatory effects on murine dendritic 
cells. Toxicological Sciences 124(2):327-338  
Blackburn CC, Manley NR (2004) Developing a new paradigm for thymus 
organogenesis. Nature Reviews Immunology 4(4):278  
Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. International 
journal of nanomedicine 10:975  
Camacho IA, Singh N, Hegde VL, Nagarkatti M, Nagarkatti PS (2005b) Treatment of 
mice with 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon 
receptor-dependent nuclear translocation of NF-κB and expression of Fas 
ligand in thymic stromal cells and consequent apoptosis in T cells. The 
Journal of Immunology 175(1):90-103  
Carlstedt-Duke JM (1979) Tissue distribution of the receptor for 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin in the rat. Cancer research 39(8):3172-3176  
Cepeda S, Griffith AV (2017) Thymic stromal cells: Roles in atrophy and age-
associated dysfunction of the thymus. Experimental gerontology  
Coder BD, Wang H, Ruan L, Su D-M (2015) Thymic involution perturbs negative 
selection leading to autoreactive T cells that induce chronic inflammation. 
The Journal of Immunology:1500082  
 
 32
Connor K, Finley B (2003) Naturally occurring ah-receptor agonists in foods: 
Implications regarding dietary dioxin exposure and health risk. Human and 
Ecological Risk Assessment 9(7):1747-1763  
Denison MS, Nagy SR (2003) Activation of the aryl hydrocarbon receptor by 
structurally diverse exogenous and endogenous chemicals. Annual review of 
pharmacology and toxicology 43(1):309-334  
Dolwick KM, Swanson HI, Bradfield CA (1993) In vitro analysis of Ah receptor 
domains involved in ligand-activated DNA recognition. Proceedings of the 
National Academy of Sciences 90(18):8566-8570  
Ema M, Ohe N, Suzuki M, et al. (1994) Dioxin binding activities of polymorphic forms 
of mouse and human arylhydrocarbon receptors. Journal of Biological 
Chemistry 269(44):27337-27343  
Esser C, Rannug A (2015) The aryl hydrocarbon receptor in barrier organ 
physiology, immunology, and toxicology. Pharmacological reviews 
67(2):259-279  
Esser C, Welzel M (1993) Ontogenic development of murine fetal thymocytes is 
accelerated by 3, 3′, 4, 4′-tetrachlorobiphenyl. International journal of 
immunopharmacology 15(8):841-852  
Gagliani N, Vesely MC, Iseppon A, et al. (2015) Th17 cells transdifferentiate into 
regulatory T cells during resolution of inflammation. Nature 523(7559):221-
5 doi:10.1038/nature14452 
Goudot C, Coillard A, Villani A-C, et al. (2017) Aryl hydrocarbon receptor controls 
monocyte differentiation into dendritic cells versus macrophages. Immunity 
47(3):582-596. e6  
Hanieh H (2014) Toward understanding the role of aryl hydrocarbon receptor in the 
immune system: current progress and future trends. BioMed research 
international 2014:520763 doi:10.1155/2014/520763 
Harper PA, Riddick DS, Okey AB (2006) Regulating the regulator: factors that 
control levels and activity of the aryl hydrocarbon receptor. Biochemical 
pharmacology 72(3):267-279  
Harris M, Moore J, Vos J, Gupta B (1973) General biological effects of TCDD in 
laboratory animals. Environmental health perspectives 5:101  
Haynes L, Swain SL (2006) Why aging T cells fail: implications for vaccination. 
Immunity 24(6):663-666  
Holladay S, Lindstrom P, Blaylock B, et al. (1991) Perinatal thymocyte antigen 
expression and postnatal immune development altered by gestational 
exposure to tetrachlorodibenzo‐p‐dioxin (TCDD). Teratology 44(4):385-
393  
Hubbard TD, Murray IA, Bisson WH, et al. (2016) Divergent Ah Receptor Ligand 
Selectivity during Hominin Evolution. Mol Biol Evol 33(10):2648-58 
doi:10.1093/molbev/msw143 
Kamath AB, Nagarkatti PS, Nagarkatti M (1998) Characterization of Phenotypic 
Alterations Induced by 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin on 
Thymocytesin Vivoand Its Effect on Apoptosis. Toxicology and applied 
pharmacology 150(1):117-124  
 
 33
Kamath AB, Xu H, Nagarkatti PS, Nagarkatti M (1997) Evidence for the induction of 
apoptosis in thymocytes by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxinin vivo. 
Toxicology and applied pharmacology 142(2):367-377  
Kambayashi T, Laufer TM (2014) Atypical MHC class II-expressing antigen-
presenting cells: can anything replace a dendritic cell? Nature reviews 
Immunology 14(11):719  
Kerkvliet NI (2012) TCDD: an environmental immunotoxicant reveals a novel 
pathway of immunoregulation—a 30-year odyssey. Toxicologic pathology 
40(2):138-142  
Knight SC, Iqball S, Roberts MS, Macatonia S, Bedford PA (1998) Transfer of antigen 
between dendritic cells in the stimulation of primary T cell proliferation. 
European journal of immunology 28(5):1636-1644  
Kouri RE, Ratrie H, Atlas SA, Niwa A, Nebert DW (1974) Aryl hydrocarbon 
hydroxylase induction in human lymphocyte cultures by 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin. Life sciences 15(9):1585-1595  
Kreitinger JM, Beamer CA, Shepherd DM (2016) Environmental immunology: 
lessons learned from exposure to a select panel of immunotoxicants. The 
Journal of Immunology 196(8):3217-3225  
Lai ZW, Kremer J, Gleichmann E, Esser C (1994) 3, 3′, 4, 4′‐Tetrachlorobiphenyl 
Inhibits Proliferation of Immature Thymocytes in Fetal Thymus Organ 
Culture. Scandinavian journal of immunology 39(5):480-488  
Lee YH, Lin CH, Hsu PC, et al. (2015b) Aryl hydrocarbon receptor mediates both 
proinflammatory and anti‐inflammatory effects in lipopolysaccharide‐
activated microglia. Glia 63(7):1138-1154  
Lepletier A, Chidgey AP, Savino W (2015) Perspectives for improvement of the 
thymic microenvironment through manipulation of thymic epithelial cells: a 
mini-review. Gerontology 61(6):504-514  
Li S, Pei X, Zhang W, Xie HQ, Zhao B (2014) Functional analysis of the dioxin 
response elements (DREs) of the murine CYP1A1 gene promoter: beyond the 
core DRE sequence. International journal of molecular sciences 15(4):6475-
6487  
Lundberg K, Grönvik K-O, Goldschmidt TJ, Klareskog L, Dencker L (1990) 2, 3, 7, 8-
Tetrachlorodibenzo-p-dioxin (TCDD) alters intrathymic T-cell development 
in mice. Chemico-biological interactions 74(1-2):179-193  
Lutz CT, Browne G, Petzold CR (1998) Methylcholanthrene causes increased 
thymocyte apoptosis. Toxicology 128(2):151-167  
Masters A, Haynes L, Su DM, Palmer D (2017) Immune senescence: significance of 
the stromal microenvironment. Clinical & Experimental Immunology 
187(1):6-15  
Merad M, Sathe P, Helft J, Miller J, Mortha A (2013) The dendritic cell lineage: 
ontogeny and function of dendritic cells and their subsets in the steady state 
and the inflamed setting. Annual review of immunology 31:563-604  
Miniero R, De Felip E, Ferri F, Di Domenico A (2001) An overview of TCDD half-life 
in mammals and its correlation to body weight. Chemosphere 43(4-7):839-
844  
 
 34
Mo R, Chen J, Han Y, et al. (2003) T cell chemokine receptor expression in aging. The 
Journal of Immunology 170(2):895-904  
Murphy K, Weaver C (2016) Janeway's immunobiology. Garland Science 
Murray JM, Kaufmann GR, Hodgkin PD, et al. (2003) Naive T cells are maintained by 
thymic output in early ages but by proliferation without phenotypic change 
after age twenty. Immunology and Cell Biology 81(6):487  
Nikolaidis E, Brunström B, Dencker L (1988) Effects of the TCDD congeners 3, 3′, 
4, 4′-tetrachlorobiphenyl and 3, 3′, 4, 4′-tetrachloroazoxybenzene on 
lymphoid development in the bursa of Fabricius of the chick embryo. 
Toxicology and applied pharmacology 92(2):315-323  
Nukaya M, Bradfield CA (2009) Conserved genomic structure of the Cyp1a1 and 
Cyp1a2 loci and their dioxin responsive elements cluster. Biochemical 
pharmacology 77(4):654-659  
Okey A, Bondy G, Mason M, et al. (1979) Regulatory gene product of the Ah locus. 
Characterization of the cytosolic inducer-receptor complex and evidence for 
its nuclear translocation. Journal of Biological Chemistry 254(22):11636-
11648  
Pearse G (2006) Normal structure, function and histology of the thymus. Toxicologic 
pathology 34(5):504-514  
Platzer B, Richter S, Kneidinger D, Waltenberger D, Woisetschläger M, Strobl H 
(2009) Aryl hydrocarbon receptor activation inhibits in vitro differentiation 
of human monocytes and Langerhans dendritic cells. The Journal of 
Immunology:jimmunol. 0802997  
Pohjanvirta R (2011) The AH receptor in Biology and Toxicology. John Wiley & Sons 
Poland A, Glover E (1975) Genetic expression of aryl hydrocarbon hydroxylase by 2, 
3, 7, 8-tetrachlorodibenzo-p-dioxin: evidence for a receptor mutation in 
genetically non-responsive mice. Molecular Pharmacology 11(4):389-398  
Prelog M (2006) Aging of the immune system: a risk factor for autoimmunity? 
Autoimmunity reviews 5(2):136-139  
Proietto AI, van Dommelen S, Zhou P, et al. (2008a) Dendritic cells in the thymus 
contribute to T-regulatory cell induction. Proceedings of the National 
Academy of Sciences 105(50):19869-19874  
Qiu J, Heller JJ, Guo X, et al. (2012) The aryl hydrocarbon receptor regulates gut 
immunity through modulation of innate lymphoid cells. Immunity 36(1):92-
104 doi:10.1016/j.immuni.2011.11.011 
Quintana FJ, Murugaiyan G, Farez MF, et al. (2010a) An endogenous aryl 
hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress 
experimental autoimmune encephalomyelitis. Proceedings of the National 
Academy of Sciences 107(48):20768-20773  
Quintana FJ, Murugaiyan G, Farez MF, et al. (2010c) An endogenous aryl 
hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress 
experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 
107(48):20768-73 doi:10.1073/pnas.1009201107 
Savino W (2006) The thymus is a common target organ in infectious diseases. PLoS 
pathogens 2(6):e62  
 
 35
Silverstone AE, Frazier DE, Jr., Gasiewicz TA (1994b) Alternate immune system 
targets for TCDD: lymphocyte stem cells and extrathymic T-cell development. 
Exp Clin Immunogenet 11(2-3):94-101  
Simones T, Shepherd DM (2011) Consequences of AhR activation in steady-state 
dendritic cells. Toxicol Sci 119(2):293-307 doi:10.1093/toxsci/kfq354 
Smith KJ, Murray IA, Boyer JA, Perdew GH (2018) Allelic variants of the aryl 
hydrocarbon receptor differentially influence UVB-mediated skin 
inflammatory responses in SKH1 mice. Toxicology 394:27-34  
Song J, Clagett-Dame M, Peterson RE, et al. (2002) A ligand for the aryl hydrocarbon 
receptor isolated from lung. Proceedings of the National Academy of Sciences 
99(23):14694-14699  
Staples JE, Murante FG, Fiore NC, Gasiewicz TA, Silverstone AE (1998) Thymic 
alterations induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin are strictly 
dependent on aryl hydrocarbon receptor activation in hemopoietic cells. J 
Immunol 160(8):3844-54  
Stockinger B, Meglio PD, Gialitakis M, Duarte JH (2014) The aryl hydrocarbon 
receptor: multitasking in the immune system. Annual review of immunology 
32:403-432  
Surh CD, Sprent J (2000) Homeostatic T cell proliferation: how far can T cells be 
activated to self-ligands? Journal of Experimental Medicine 192(4):F9-F14  
Swanson HI, Chan WK, Bradfield CA (1995) DNA binding specificities and pairing 
rules of the Ah receptor, ARNT, and SIM proteins. Journal of Biological 
Chemistry 270(44):26292-26302  
Temchura VV, Frericks M, Nacken W, Esser C (2005) Role of the aryl hydrocarbon 
receptor in thymocyte emigration in vivo. European journal of immunology 
35(9):2738-2747  
Vogel CF, Goth SR, Dong B, Pessah IN, Matsumura F (2008) Aryl hydrocarbon 
receptor signaling mediates expression of indoleamine 2, 3-dioxygenase. 
Biochemical and biophysical research communications 375(3):331-335  
Vorderstrasse BA, Kerkvliet NI (2001) 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin affects 
the number and function of murine splenic dendritic cells and their 
expression of accessory molecules. Toxicology and applied pharmacology 
171(2):117-125  
Wang C, Ye Z, Kijlstra A, Zhou Y, Yang P (2014) Activation of the aryl hydrocarbon 
receptor affects activation and function of human monocyte‐derived 
dendritic cells. Clinical & Experimental Immunology 177(2):521-530  
Winans B, Nagari A, Chae M, et al. (2015) Linking the Aryl Hydrocarbon Receptor 
with Altered DNA Methylation Patterns and Developmentally Induced 
Aberrant Antiviral CD8+ T Cell Responses. The Journal of Immunology 
194(9):4446-4457  
Wright EJ, De Castro KP, Joshi AD, Elferink CJ (2017) Canonical and non-canonical 
aryl hydrocarbon receptor signaling pathways. Current Opinion in 
Toxicology 2:87-92  
 
 36
Yao EF, Denison MS (1992) DNA sequence determinants for binding of transformed 
Ah receptor to a dioxin-responsive enhancer. Biochemistry 31(21):5060-
5067  
 
 
CHAPTER 2: TARGETED DELETION OF THE ARYL HYDROCARBON 
RECEPTOR IN DENDRITIC CELLS PREVENTS THYMIC ATROPHY IN 
RESPONSE TO DIOXIN. 
 
In Press in Archives of Toxicology 
 
Authors 
Celine A. Beamer, Joanna M. Kreitinger, Shelby L. Cole, David M. Shepherd 
 
Corresponding Author 
David M. Shepherd, Ph.D. 
University of Montana 
Department of Biomedical and Pharmaceutical Sciences 
32 Campus Drive, Skaggs Building Room 284 
Missoula, MT 59812 
406-243-2224 (phone) 
406-243-2807 (fax) 
david.shepherd@umontana.edu 
 
Keywords:  involution, TCDD, ITE, I3C, AhRd, apoptosis 
 
Grant Funding: Research reported in this publication was supported by the 
National Institute of Environmental Health Sciences and the National Institute of General 
Medical Sciences of the National Institutes of Health under grant numbers R01-
ES013784 (DMS), P30-GM103338, P20-GM103546. JMK was supported by The 
American Association of Immunologists through a Careers in Immunology Fellowship.  
The content is solely the responsibility of the authors and does not necessarily represent 
the official views of the National Institutes of Health. 
  
 
 38
Abstract  
In nearly every species examined, administration of the persistent environmental 
pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin, TCDD) causes profound immune 
suppression and thymic atrophy in an aryl hydrocarbon receptor (AhR)-dependent 
manner. Moreover, TCDD alters the development and differentiation of thymocytes, 
resulting in decreases in the relative proportion and absolute number of double positive 
(DP, CD4+CD8+) thymocytes, as well as an enrichment in the relative proportion and 
absolute number of double negative (DN, CD4-CD8-) and single positive (SP) CD4+CD8- 
and CD4-CD8+ thymocytes. Previous studies suggested that the target for TCDD-induced 
thymic atrophy resides within the hematopoietic compartment and implicated apoptosis, 
proliferation arrest of thymic progenitors, and emigration of DN thymocytes to the 
periphery as potential contributors to TCDD-induced thymic atrophy. However, the 
precise cellular and molecular mechanisms involved remain largely unknown.  Our 
results show that administration of 10 g/kg TCDD and 8 mg/kg 2-(1H-Indol-3-
ylcarbonyl)-4-thiazolecarboxylic acid methyl ester (ITE) induced AhR-dependent thymic 
atrophy in mice on day 7 following exposure, whereas 100 mg/kg indole 3-carbinol (I3C) 
did not. Though our studies demonstrate that TCDD triggers a 2-fold increase in the 
frequency of apoptotic thymocytes, TCDD-induced thymic atrophy is not dependent on 
Fas-FasL interactions and thus, enhanced apoptosis is unlikely to be a major mechanistic 
contributor. Finally, our results show that activation of the AhR in CD11c+ dendritic cells 
is directly responsible for TCDD-induced alterations in the development and 
differentiation of thymocytes, which results in thymic atrophy. Collectively, these results 
suggest that CD11c+ dendritic cells play a critical role in mediating TCDD-induced 
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thymic atrophy and disruption of T lymphocyte development and differentiation in the 
thymus. 
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Introduction 
 
The thymus is a complex, specialized organ that is responsible for the maturation 
and education of most peripheral T cells. Progenitor cells enter the thymus from the 
blood stream after originating in the bone marrow and/or fetal liver. Once in the thymus, 
these cells progress through multiple developmental stages that can be delineated by cell 
surface markers such as CD3, CD4, and CD8. In the earliest stage, classified as double 
negative (DN) thymocytes, cells do not express any of these markers. Subsequently, cell 
surface markers are up-regulated to give rise to CD4+CD8+ double positive (DP) cells, 
which then undergo a rigorous selection process eventually down-regulating either CD4 
or CD8 expression to become CD4+ or CD8+ single-positive (SP) cells, which are 
released into the periphery. Self-reactive cells failing negative selection are removed via 
apoptotic pathways, and mature, self-tolerant SP thymocytes are released into the 
periphery as naïve Th cells (CD4) or cytotoxic T cells (CD8). Because ongoing 
thymopoiesis is essential for the development and maintenance of a healthy immune 
system, agents that trigger thymic atrophy may decrease host ability to reconstitute the 
peripheral T cell repertoire or respond to new antigens. Similarly, because the overall 
process of maturation and education of T cells is orchestrated, to a degree, by the 
supporting cells of the stromal network, which includes thymic epithelial cells, dendritic 
cells, and macrophages (Nowell et al. 2007), agents that induce thymic atrophy may be 
acting on a variety of cellular targets. 
The aryl hydrocarbon receptor (AhR) is a ligand activated transcription factor 
belonging to the Per-ARNT-SIM-basic-helix-loop-helix (PAS/bHLH) protein family, 
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which mediates a wide range of biological responses resulting from exposures to both 
natural and synthetic ligands (Gu et al. 2000; Okey 2007; Pohjanvirta 2011). AhR was 
first identified in the early 1970s and has since been shown to have dual roles as an 
activator of xenobiotic metabolism and as a participant in normal homeostasis, 
organogenesis, and immune modulation (Nebert and Gelboin 1968; Nebert and Gelboin 
1969; Okey 2007; Wright et al. 2017). Nevertheless, details of the cellular and molecular 
mechanisms underlying many AhR-dependent physiological and toxicological effects are 
currently unknown. 
Halogenated dioxins, biphenyls, and polycyclic aromatic hydrocarbons represent 
the best-characterized high-affinity, planar, and hydrophobic ligands of the AhR. 
Although numerous high affinity AhR ligands have since been discovered, the potent and 
persistent environmental pollutant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) 
remains the prototypic AhR ligand for mechanistic studies (Kerkvliet 2012; Poland et al. 
1976). Exposure of laboratory rodents to TCDD and TCDD-like chemicals profoundly 
affects the immune system, causing immunosuppression typified by suppressed cellular 
immunity, inhibition of antibody production, and thymic atrophy in a variety of animal 
species (Faith and Luster 1979; Funatake et al. 2005; Harris et al. 1973; Kerkvliet 2002; 
Poland and Glover 1980; Van Loveren et al. 1991; Vecchi et al. 1980) via direct effects 
of AhR activation (Fernandez-Salguero et al. 1996; Harrill et al. 2016; Staples et al. 
1998). C57Bl/6 mice, which harbor the AhRb allele that codes for a receptor with a high 
binding affinity for agonists, exhibit a decrease in thymic weight and cellularity as early 
as three days after exposure to a single 30 g/kg dose of TCDD (Laiosa et al. 2003a).  
Maximal decline in thymocyte cellularity emerges 10 days later, yet recovery to near 
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baseline levels does not occur until approximately 30 days after exposure (Laiosa et al. 
2003a).   
During TCDD-induced thymic atrophy, the thymus undergoes a marked reduction 
in the frequency of DP thymocytes, as well as a relative increase in the frequency of DN 
and SP thymocytes. Moreover, based upon the observed values for thymic cellularity, 
these shifts in thymocyte subset frequencies correspond to significant decreases in the 
absolute number of thymocytes in each of the four subpopulations (Kamath et al. 1998; 
Kamath et al. 1997; Lundberg et al. 1990).  Although the precise cellular and molecular 
mechanisms involved remain largely unknown, previous studies demonstrated that the 
target for TCDD-induced thymic atrophy resides within the hematopoietic compartment 
and implicated reduced proliferation of DN precursor thymocytes (Lai et al. 1994), 
enhanced apoptosis via Fas:FasL interactions at the DP stage (Camacho et al. 2005b), and 
enhanced emigration of thymocytes (Temchura et al. 2005), or a combination of these 
possible mechanisms. Therefore, it was of great interest to evaluate TCDD-induced 
thymic atrophy in naïve wild-type mice (C57Bl/6), mice expressing the low affinity AhR 
(AhRd), and AhR conditional knockout mice (LyzMCreAhRfx, CD11cCreAhRfx, 
RORcCreAhRfx, and FoxN1CreAhRfx).  Furthermore, we assessed whether an endogenous, 
non-toxic AhR ligand 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester 
(ITE) (Abron et al. 2018; Benson and Shepherd 2011b; Song et al. 2002) and a dietary 
AhR ligand, indole 3-carbinol (I3C) (Benson and Shepherd 2011b; Bjeldanes et al. 1991; 
Connor and Finley 2003) exhibited thymotoxic effects similar to TCDD. The findings 
presented here extend our understanding of how activation of the AhR contributes to 
thymic atrophy and mediates immune suppression. 
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Materials and Methods 
Chemicals  
2,3,7,8, tetrachlorodibenzo-p-dioxin (dioxin, TCDD) was obtained from 
Cambridge Isotopes (Cambridge, MA). A 1 mg/mL stock solution of TCDD in 
anisole/peanut oil was diluted to yield treatment solutions containing 1 or 10 μg/mL in 
peanut oil.  2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid methyl ester (ITE) was 
obtained from Tocris (Bio-techne brand, Minneapolis, MN). A 20 mg/mL stock solution 
of ITE in DMSO was diluted to yield a treatment solution containing 0.8 mg/mL in 
peanut oil.  Indole 3-carbinol (I3C), obtained from Sigma-Aldrich (St. Louis, MO), was 
suspended in peanut oil (10 mg/mL). The estimated half-life of TCDD is approximately 
10 days in mice (Birnbaum 1986; Gasiewicz et al. 1983), whereas the in vivo absorption, 
metabolism, distribution, and excretion rates of ITE and I3C in mice remain largely 
undetermined.  Therefore, we selected the dose and route of exposure based upon earlier 
reports, thus integrating our results with previous findings in other model systems (Abron 
et al. 2018; Benson and Shepherd 2011a; Boule et al. 2018b; Nugent et al. 2013; 
Quintana et al. 2010c; Singh et al. 2016).  
 
Biohazard precaution 
TCDD is highly toxic and a known human carcinogen. All personnel were 
instructed in safe handling procedures. Proper personal protective equipment (e.g. lab 
coats, gloves and masks) were worn at all times, and contaminated materials were 
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collected separately for hazardous waste disposal. TCDD-treated mice were housed 
separately, and their carcasses and bedding regarded as contaminated materials. 
 
Mice 
Breeding pairs of mice were originally purchased from The Jackson Laboratory 
(Bar Harbor, ME) and maintained as both individual colonies and crossed strains to yield 
AhR conditional knockouts (supplemental Table 1). Tails snips were digested in direct 
PCR lysis reagent according to the manufacturer’s protocol (Viagen Biotech, Los 
Angeles, CA). Mice of the correct genotype were identified according to PCR conditions 
furnished by the Jackson Laboratory, and littermates were used as controls. All mice 
were maintained in microisolator cages in the University of Montana specific pathogen-
free (SPF) laboratory animal facility, and provided breeder (Teklad 2019, Envigo, 
Denver, CO) or standard rodent chow (Teklad 2020x, Envigo) and tap water ad libitum. 
All animal use procedures were in accordance with NIH and University of Montana 
IACUC guidelines.  
 
In Vivo Exposure 
Naïve, adult (6-10-week-old) mice received 10 or 100 μg TCDD/kg, 1 to 8 mg/kg 
ITE, or 100 mg/kg I3C (Camacho et al. 2005b; Nguyen and Bradfield 2007; Quintana et 
al. 2010a; Singh et al. 2014) via oral gavage (p.o.) or intraperitoneal injection (i.p.) as 
described in the appropriate results sections.  Control mice received solvent/peanut oil or 
a peanut oil only vehicle control. Each experiment was performed in duplicate or 
triplicate with age-matched littermates (+7 days), containing a minimum of three mice of 
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each sex for n=6 per treatment group.  Mice were weighed daily, tissues collected 7 days 
later, and analyzed individually. 
 
Cell Isolation  
Following euthanasia by CO2 asphyxiation, body weights were recorded and 
thymi removed free of lymph nodes and blood vessels.  Individual thymi were weighed 
and pressed through a 70 m sterile cell strainer with the flat end of a 1 mL syringe 
plunger to release the cells into cold complete RPMI (cRPMI) media supplemented with 
10% FBS (Atlanta Biologicals, Atlanta, GA), 50 M β-mercaptoethanol, 20 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 10 mM sodium pyruvate, and 50 g/ml 
gentamicin (Gibco, Grand Island, NY) (Corning, Manassas, VA). Thymocytes were 
pelleted by centrifugation at 1500 rpm for 5 minutes, re-suspended in fresh cRPMI, and 
maintained on ice. 
 
Flow cytometry 
Single cell suspensions of thymocytes were washed once with cRPMI and re-
suspended in 100 μl of purified rat anti-mouse CD16/CD32 (2.4G2, Tonbo, San Diego, 
CA) diluted 1:100 in PBS containing 1% bovine serum albumin and 0.1% sodium azide 
(PAB) to block Fc receptors. 2 x 106 thymocytes were immunostained for 30 minutes on 
ice with titrated monoclonal antibodies specific to CD3 PerCPCy5.5 (145-2C11, 
Tonbo), CD4 FITC or redfluor 710 (RM4-5, Tonbo), and CD8 PE-Cy7 (53-6.7, Tonbo) 
to identify live, propidium iodide (PI, Tonbo) negative singlet thymocytes. Another 2 x 
106 thymocytes were immunostained for 30 minutes on ice with monoclonal antibodies 
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specific to CD45 v450 (30-F11, Tonbo), CD4 FITC (RM4-5, Tonbo), CD8α PE-Cy7 (53-
6.7, Tonbo), CD11c PE (HL3, BD Pharmingen, San Diego, CA), Fas Alexa Fluor 647 
(Jo2, BD Pharmingen), FasL PerCP Cy5.5 (MFL3, BD Pharmingen) to identify cell 
surface expression of Fas and FasL.  Alternatively, 2 x 106 thymocytes were 
immunostained with monoclonal antibodies specific to CD4 FITC (RM4-5, Tonbo), 
CD8α PE-Cy7 (53-6.7, Tonbo), in addition to Annexin V and 7-AAD staining solution 
according to the manufacturer’s instructions (Tonbo). Unstained, single stained, and 
fluorescence minus one controls were used to set positive/negative gating. Cells were 
washed twice with 1 mL PAB and re-suspended in 350 L of PAB and acquisition was 
performed on a FACS Aria II flow cytometer using FACS Diva software (v 6.1.2, Becton 
Dickinson, Franklin Lakes, NJ). Compensation of the spectral overlap was performed 
using One Comp compensation control beads (BD Biosciences, San Diego, CA) in 
combination with single stained controls where appropriate.  Data files were exported as 
FCS 3.1 files and analyzed by Flow Logic (v 4.0, Miltenyi, Auburn,CA). 
 
RNA isolation and RT-qPCR 
 Total RNA was extracted from 5 x 106 thymocytes using TRIzol reagents 
(Invitrogen) or a RNeasy mini kit (Qiagen, Germantown, MD) according to the 
manufacturer protocols. Two-step qRT-PCR was performed by synthesizing cDNA using 
iScript Reverse Transcription Supermix (BioRad, Hercules, CA) followed by RT-qPCR 
relative quantification of 50 ng cDNA per reaction using CFX Connect, SSO Advanced 
Universal SYBR Green Master Mix, and PrimePCR validated primers for murine 
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GAPDH, Hprt, Tbp, Fas, and FasL (BioRad, Hercules, CA). The data were normalized to 
the reference genes Hprt, Tbp, and GAPDH.  
 
Statistical Analysis 
 For each parameter, the values for individual experiments were averaged and the 
standard error calculated.  Student t-tests, one-way or two-way ANOVA were performed 
using Prism 7 (GraphPad, La Jolla, CA). A p value of ≤ 0.05 was considered significant.  
 
Results 
ITE, but not I3C, induces thymic atrophy 
Although AhR activation promotes immunoregulatory responses in a ligand-
dependent manner (Ehrlich et al. 2018), little is known about the thymotoxic effects of 
other AhR ligand chemotypes. To test the hypothesis that activation of the AhR induces 
thymic atrophy in a ligand-dependent manner, C57Bl/6 mice were gavaged with an 
endogenous ligand (ITE) (Song et al. 2002) and a dietary ligand (I3C) (Connor and 
Finley 2003), with chemical structures that are distinct from TCDD (Figure 1A). The 
dose and route of exposure to each chemical were selected based on prior reports, thus 
simplifying integration of our results with previous findings (Benson et al. 2012b; Boule 
et al. 2018b; Quintana et al. 2010b).  After daily administration of 8 mg/kg ITE, C57Bl/6 
mice exhibited extensive thymic atrophy as evidenced by a significant loss in organ 
weight (52% decrease) and a dramatic reduction in thymic cellularity (73% decrease) 
relative to vehicle control on day 7. In contrast, administration of 100 mg/kg I3C to 
C57Bl/6 mice every other day resulted in a trend towards increased thymic weight and a 
 
 48
significant increase in cellularity (30% increase) relative to vehicle control on day 7 
(Figure 1B and 1C).  No sex-specific effects were observed at day 7 with ITE or I3C 
(data not shown). Because ITE and I3C differentially affected thymic weight and 
cellularity, we also compared effects on intra-thymic differentiation by assessing the 
surface expression of CD4 and CD8 on live thymocytes via flow cytometry (Figure 2). 
Although administration of ITE revealed a trend similar to TCDD with regards to a 
significant reduction in the frequency of DP and increase in the frequency of DN and 
CD4+ SP thymocytes, no difference was observed in the frequency of CD8+ SP 
thymocytes compared to vehicle control.  Lastly, administration of I3C to C57Bl/6 mice 
resulted in no significant changes in the development and/or differentiation of any 
CD4/CD8 thymocyte subsets examined (Figure 2.1 and Figure 2.2).  Together, these data 
show that activation of the AhR induces thymic atrophy in a ligand-dependent manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 49
Figure 2. 1 ITE, but not I3C, induces thymic atrophy. 
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Figure 2.1 ITE, but not I3C, induces thymic atrophy. 
  
Naïve wild-type mice (C57Bl/6) were gavaged with 3 chemically distinct AhR 
ligands (A): TCDD (10 µg/kg), ITE (8 mg/kg), or I3C (100 mg/kg). Three 
indicators of toxicity: body weight (data not shown), thymus weight (B), and 
thymus cell numbers (C) were measured on day 7 to evaluate toxicity and thymic 
atrophy after administration of TCDD, ITE, and I3C. Data represent one of two 
independent experiments, n=3-5 per treatment group, mean + SEM; 1-way 
ANOVA, *p < 0.05 vehicle. 
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Figure 2. 2 Comparison of CD4/CD8 thymocyte subsets from vehicle, TCDD, ITE, and I3C 
exposed mice 
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Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle, TCDD, ITE, 
and I3C exposed mice.  
 
C57Bl/6 mice were gavaged with the appropriate vehicle control, TCDD (10 µg/kg, 
once), ITE (8 mg/kg daily), or I3C (100 mg/kg every other day).   Representative 
contour plots gating on live thymocytes revealed a significant decline in the 
frequency of CD4+CD8+ DP thymocytes, as well as a relative enrichment in the 
percent of CD4-CD8- DN and CD4+CD8- and CD4-CD8+ SP thymocytes in 10 g/kg 
TCDD- and 8 mg/kg ITE-treated mice compared to vehicle controls on day 7.  These 
shifts in CD4/CD8 thymocyte subsets were not observed in mice treated with 100 
mg/kg I3C. The mean percentages of the CD4/CD8 thymocyte subsets + SEM are 
indicated in the plots. Data represent one of two independent experiments, n=3-5 per 
treatment group; 1-way ANOVA, *p < 0.05 vehicle. 
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ITE induces thymic atrophy in a dose- and AhR-dependent manner 
 
 Although exposure to ITE in vitro caused dose-dependent alterations in 
thymocyte differentiation and maturation that paralleled those observed following in vitro 
exposure to TCDD, previous reports did not detect changes in thymus weight 12 days 
following a single delivery of 5.6 mg/kg ITE (i.v.) (Henry et al. 2006).  To test the 
hypothesis that ITE induces thymic atrophy in an AhR-dependent manner, C57Bl/6 and 
low affinity AhRd mice were gavaged daily with a previously described 
immunosuppressive dose of ITE (Abron et al. 2018; Henry et al. 2006; Nugent et al. 
2013; Quintana et al. 2010b) and tissues analyzed at day 7.  First, we confirmed that mice 
expressing the low affinity AhRd allele do not exhibit thymic atrophy when exposed to 10 
g/kg TCDD and that a 10-fold higher dose of TCDD (e.g. 100 g/kg) in AhRd mice 
overcame the low-affinity receptor, resulting in thymic atrophy (Supp. Figure 2.1 and 
2.2). This supplemental data support the use of AhRd mice as a model to evaluate ligands 
for AhR-dependent effects.  ITE exposure to naive C57Bl/6 mice resulted in thymic 
atrophy as evidenced by a significant decline in organ weight (49% decrease) and a 
reduction in thymic cellularity (73% decrease) relative to vehicle control. In contrast, 
AhRd mice were refractory to the same 8 mg/kg dose of ITE with regards to thymic 
weight (Figure 2.3A) and cellularity (Figure 2.3B).  Likewise, the dose-dependent effects 
of ITE were scrutinized in C57Bl/6 mice by assessing thymic weight and cellularity.  
Daily administration of 1, 2, 4, and 8 mg/kg ITE (p.o.) resulted in dose-dependent thymic 
atrophy as evidenced by a decline in organ weight of 13%, 25%, 30% and 35%, 
respectively (Figure 2.3C) and a dramatic decrease in thymic cellularity of 25%, 25%, 
40% and 50% (Figure 2.3D) respectively, in C57Bl/6 mice relative to vehicle control on 
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day 7.  Lastly, comparable levels of thymic atrophy were observed following daily 
administration of 1 mg/kg ITE i.p. and 4 mg/kg ITE p.o. (data not shown).  
 
Figure 2. 3 ITE-induced thymic atrophy in an AhR- and dose-dependent manner. 
 
 
 
 
 
 
Figure 2.3. ITE-induced thymic atrophy in an AhR- and dose-dependent manner. 
  
Naïve wild-type mice (C57Bl/6) and mice expressing the low affinity receptor (AhRd 
mice) were gavaged with vehicle (anisole/peanut oil) or ITE (8 mg/kg).   Three indicators 
of toxicity: body weight (data not shown), thymus weight (A), and thymus cell number 
(B) were measured on day 7 to evaluate toxicity and thymic atrophy. n=5-6 mice per 
treatment group, mean + SEM; 1-way ANOVA, *p < 0.05 vehicle. An additional cohort 
of C57Bl/6 mice were gavaged with vehicle (anisole/peanut oil) or increasing doses of 
ITE (1, 2, 4, or 8 mg/kg).   Three indicators of toxicity: body weight (data not shown), 
thymus weight (C), and thymus cell number (D) were measured on day 7 to evaluate 
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toxicity and thymic atrophy.  n=5-6 mice per treatment group, mean + SEM; 1-way 
ANOVA, *p < 0.05 vehicle. 
 
Dioxin-mediated thymic atrophy is not dependent on apoptosis via Fas:FasL interactions  
 
  Since TCDD has been reported to initiate apoptosis in immature thymocytes 
(Fisher et al. 2004; Rhile et al. 1996) and Fas:FasL interactions have been implicated in 
this process (Dencker et al. 1985; Kamath et al. 1999a), C57Bl/6 mice were treated with 
10 g/kg TCDD and the degree of apoptosis measured by assessing the expression of 
7AAD and Annexin V, as well as Fas and FasL on thymocytes via flow cytometry.  
Representative dot plots gating on singlet thymocytes revealed a slight, but statistically 
significant increase in the frequency of Annexin V+7AAD- apoptotic thymocytes in 10 
g/kg TCDD-treated mice (6.5% + 0.8 of thymocytes) compared to vehicle (3.8% + 0.6 
of thymocytes) on day 7 (Figure 2.4A).  However, this did not correspond to a significant 
increase in the absolute number of apoptotic cells—perhaps due to the massive decline in 
thymus cellularity (data not shown). Moreover, representative dot plots gating on 
Annexin V+7AAD- apoptotic thymocytes revealed that the majority of apoptotic cells 
were DP thymocytes, followed by DN and CD4+ SP thymocytes, with very few apoptotic 
cells observed in the CD8+ SP subset.  In contrast, TCDD exposed animals exhibited a 
distribution shift at day 7—resulting in an increased frequency of Annexin V+7AAD- 
apoptotic thymocytes within the DN, CD4+, and CD8+ SP thymocytes and a decreased 
frequency of Annexin V+7AAD- apoptotic thymocytes being of the DP thymocyte subset 
(Figure 2.4A and 2.4B).  Additionally, C57Bl/6 mice were treated with 10 g/kg TCDD 
and Fas-FasL gene expression was analyzed in freshly isolated thymocytes on days 3, 7, 
and 14 post exposure. TCDD resulted in no change in either Fas or FasL gene expression 
as measured by quantitative RT-PCR (data not shown).  Furthermore, 3 days after 
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administration of TCDD to C57Bl/6 mice, there were no observable effects on the 
frequency nor the MFI of Fas and FasL expression on live CD45+ thymocytes relative to 
vehicle controls (Figure 2.5a). Because previous studies reported that dioxin induced 
FasL-dependent thymocyte cell death (Camacho et al. 2005a; Kamath et al. 1999b), we 
examined the role of Fas-FasL signaling in TCDD-induced thymic atrophy using FasL-
deficient (gld/gld) mice.  FasL deficient mice were exposed to 10 g/kg TCDD (p.o.) and 
their thymic weight and cellularity measured on day 7. Contrary to a previous report 
(Kamath et al. 1999b), FasL-deficient mice in our experiments were not protected against 
TCDD-induced thymic atrophy and exhibited significant reductions in thymic weight 
(60% decrease) and cellularity (70% decrease) comparable to wild-type C57Bl/6 mice 
(Figure 2.5B).  Similarly, representative dot plots (gating on live thymocytes) revealed a 
significant decline in the frequency of DP thymocytes, as well as a relative enrichment in 
the percent of DN and CD4+ and CD8+ SP thymocytes in 10 g/kg TCDD-treated mice 
compared to vehicle control (Figure 2.5C).   
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Figure 2. 4 The effect of TCDD on apoptotic thymocytes. 
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Figure 2.4. The effect of TCDD on apoptotic thymocytes.  
Naïve wild-type mice (C57Bl/6) were gavaged with vehicle (anisole/peanut oil) or 
TCDD (10 g/kg). Representative contour plots gating on 7-AAD+Annexin V+ 
thymocytes revealed a significant increase in the frequency of apoptotic thymocytes (A), 
as well as a dramatic shift in the distribution of thymocytes which were undergoing 
apoptosis 7 days following exposure to TCDD (B).  Data represent one of two 
independent experiments, n=3-5 mice per treatment group, mean + SEM; 1-way 
ANOVA, *p < 0.05 vehicle. 
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Figure 2. 5 TCDD-mediated thymic atrophy is not dependent on Fas-FasL interactions 
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Figure 2.5. TCDD-mediated thymic atrophy is not dependent on Fas-FasL 
interactions. Naïve wild-type mice (C57Bl/6) were gavaged with vehicle 
(anisole/peanut oil) or TCDD (10 g/kg).   Representative contour plots gating on 
singlet thymocytes revealed that 3 days after administration of vehicle or 10 g/kg 
TCDD to C57Bl/6 mice, there were no observable effects on the frequency of Fas and 
FasL expression on CD45+ thymocytes relative to vehicle control (A). FasL deficient 
(gld/gld) mice were exposed to 10 g/kg TCDD and their thymic weight and 
cellularity measured on day 7 (B). Similarly, representative dot plots (gating on live 
thymocytes) revealed a significant decline in the frequency of DP thymocytes, as well 
as a relative enrichment in the percent of DN and CD4+CD8- and CD4-CD8+ SP 
thymocytes in 10 g/kg TCDD-treated FasL deficient (gld/gld) mice compared to 
vehicle control (C).  n=5 mice per treatment group, mean + SEM; t-test, *p < 0.05 
vehicle. 
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Targeted deletion of the AhR in CD11c+ dendritic cells protects against dioxin-induced 
thymic atrophy  
Previous studies revealed that the target/s for TCDD-induced thymic atrophy 
reside within the hematopoietic cells and not stromal tissues (Staples et al. 1998); 
however, it is uncertain which hematopoietically derived cells contribute to TCDD-
induced thymic atrophy.  To determine how AhR signaling in specific immune cells 
mediates TCDD-induced thymic atrophy, we generated AhR conditional knockout mice 
for myeloid derived cells (LyzMCreAhRfx), CD11c+ dendritic cells (CD11cCreAhRfx), 
RORt+ DP and SP thymocytes (RORcCreAhRfx), and thymic epithelial cells 
(FoxN1CreAhRfx). Mice were dosed with solvent/peanut oil vehicle or 100 g/kg 
TCDD—a dose of dioxin necessary to elicit thymotoxic endpoints in conditional AhRfx/fx 
mice which carry the low affinity AhRd allele (Poland and Glover 1980; Walisser et al. 
2005). Seven days later, Cre-AhRfx/fx and AhRd mice, as well as LyzMCreAhRfx, 
RORcCreAhRfx, and FoxN1CreAhRfx exhibited extensive thymic atrophy as evidenced by a 
decline in organ weight (68%, 63%, and 63% decrease, respectively) (Figure 2.6A) and a 
dramatic reduction in thymic cellularity (89%, 89%, and 82% decrease, respectively) 
(Figure 2.6B) relative to vehicle control. In contrast, CD11cCreAhRfx mice were protected 
from TCDD-induced thymic atrophy and showed no significant difference from vehicle 
controls in either thymic weight (Figure 2.6A) or cellularity (Figure 2.6B).  These 
findings led us to further investigate whether targeted deletion of the AhR in specific 
immune cell types also facilitates TCDD-induced effects on intra-thymic development 
and differentiation. Representative dot plots from AhRd, LyzMCreAhRfx, RORcCreAhRfx, 
and FoxN1CreAhRfx mice administered 100 g/kg TCDD echoed the typical alterations in 
thymocyte subsets which can be observed in wild-type mice following exposure to 
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TCDD: decreases in the frequency of DP thymocytes and increases in the frequency of 
DN, CD4+, and CD8+ SP thymocytes compared to vehicle control (data not shown).  
Importantly, representative dot plots gating on live thymocytes from CD11cCreAhRfx 
mice treated with 100 g/kg TCDD exhibited protection from TCDD-induced alterations 
in thymocyte subsets (Figure 2.7). Because conditional Cre negative x AhRfx/fx mice carry 
the low affinity AhRd allele (Poland and Glover 1980; Walisser et al. 2005), this strain 
can be utilized interchangeably with Cre-AhRfx as controls for experiments involving 
AhR conditional knockout mice (supplemental Figure 2.3). Collectively these data show 
that targeted deletion of the AhR in CD11c+ dendritic cells protects against TCDD-
induced thymic atrophy. 
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Figure 2. 6 Deletion of the AhR in CD11c+ dendritic cells protects against dioxin-
induced thymic atrophy. 
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Figure 2.6. Deletion of the AhR in CD11c+ dendritic cells protects against dioxin-
induced thymic atrophy.  
AhR conditional knockout mice were generated for myeloid derived cells 
(LyzMCreAhRfx), CD11c+ dendritic cells (CD11cCreAhRfx), RORt+ DP and SP 
thymocytes (RORcCreAhRfx), and thymic epithelial cells (FoxN1CreAhRfx). Mice were 
exposed to either solvent/peanut oil vehicle or 100 g/kg TCDD. Three indicators of 
toxicity: body weight (data not shown), thymus weight (A), and thymus cell number 
(B) were measured on day 7.  Data represent one of three independent experiments, 
n=3-4 mice per treatment group, mean + SEM; 2-way ANOVA, *p < 0.05 vehicle. 
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Figure 2. 7 Comparison of CD4/CD8 thymocyte subsets from CD11cCreAhRfx and AhRd mice 
exposed to vehicle or TCDD.   
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Figure 2.7. Comparison of CD4/CD8 thymocyte subsets from CD11cCreAhRfx and 
AhRd mice exposed to vehicle or TCDD.   
  
AhR conditional knockout and AhRd control mice were exposed to either 
solvent/peanut oil vehicle or 100 g/kg TCDD. Representative contour plots gating on 
live thymocytes revealed a significant decline in the frequency of CD4+CD8+ DP 
thymocytes, as well as a relative enrichment in the percent of CD4-CD8- DN and 
CD4+CD8- and CD4-CD8+ SP thymocytes in AhRd mice exposed to 100 g/kg TCDD 
compared to vehicle controls on day 7.  These shifts in CD4/CD8 thymocyte subsets 
were not observed in CD11cCreAhRfx mice treated with TCDD. The mean percentages 
of the CD4/CD8 thymocyte subsets + SEM are indicated in the plots. Data represent 
one of three independent experiments, n=3-4 per treatment group; 2-way ANOVA, *p 
< 0.05 vehicle. 
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Discussion 
 
Administration of dioxin (TCDD) and dioxin-like chemicals to laboratory rodents 
dramatically affects the immune system, triggering immunosuppression characterized by 
suppressed cellular immunity, inhibition of antibody production, and thymic atrophy 
(Silkworth and Antrim 1985; Silkworth et al. 1986)—effects which are dependent on the 
AhR (Fernandez-Salguero et al. 1996; Harrill et al. 2016; Staples et al. 1998). Unlike 
many nuclear receptors, the AhR is a highly promiscuous receptor, directly binding a 
wide variety of structurally diverse natural and synthetic compounds, thereby promoting 
the up- or down-regulation of a multitude of target genes in different tissues. The 
spectrum of biological effects produced by the ligand/AhR/ARNT signaling complex is 
dependent on the physicochemical characteristics and persistence of the ligand (Ehrlich et 
al. 2018).  To date, most analyses exploring AhR-induced immune modulation have 
taken advantage of TCDD’s specificity and high affinity for the AhR (6 pM – 2.4 nM), as 
well as its long half-life (~11 days in mice; 8-10 years in humans) (Miniero et al. 2001).  
However, the same properties that make TCDD an excellent tool also contribute to its 
profound toxicity. While other ligands such as ITE and indole-3-carbinol (I3C) can 
activate the AhR and have been evaluated as potential therapeutics (Abron et al. 2018; 
Quintana et al. 2010c; Yeste et al. 2012), little is known about their potential thymotoxic 
effects. Thus, the present study investigated the effects of an endogenous (ITE) and a 
dietary (I3C) ligand on thymic development and differentiation.  
Administration of 8 mg/kg ITE to C57Bl/6 mice resulted in a dramatic reduction 
in organ weight and thymic cellularity on day 7. In contrast, administration of 100 mg/kg 
 
 62
I3C to C57Bl/6 mice resulted in a slight increase in thymic weight and a significant 
increase in cellularity. Because previous studies in a murine colitis model suggested that 
sex-specific effects existed with select AhR ligands (Benson et al. 2012a), we also tested 
the hypothesis that male vs. female mice would exhibit disparate thymic atrophy 
following activation of the AhR.  Interestingly, no sex specific effects were observed 
with regards to thymic weight or cellularity following exposure to TCDD, ITE, or I3C.  
Likewise, because AhR activation by TCDD and TCDD-like compounds results in 
alterations in the frequency of thymocyte subsets, we investigated whether ITE and I3C 
similarly affected thymic development and differentiation.  Our results demonstrate for 
the first time that ITE induced thymic atrophy, as well as reduced the frequency of DP 
thymocytes and increased the frequency of DN, CD4+ and CD8+ SP thymocytes—albeit 
to a slightly lesser degree than TCDD.  These data are in contrast to a previous report 
(Henry et al. 2006), which did not detect changes in thymus weight 12 days following a 
single delivery of 5.6 mg/kg ITE (i.v.).  It is likely that the discrepancy between our 
results and the study by Henry et al., 2006 reside in the differences between dose (acute 
vs sub-acute) and route of delivery (i.v. vs. p.o.) of the AhR ligand (Boule et al. 2018b; 
Ehrlich et al. 2018).  Interestingly, I3C did not result in thymic atrophy with a slight 
increase in thymic cellularity being observed. This divergence in effects between two 
natural AhR ligands was surprising as the administered doses had both been shown to 
elicit immunosuppressive effects, and the thymus is known to be acutely sensitive to AhR 
ligands. Importantly, the previously reported immunosuppression observed with I3C 
occurred within the intestines, which given the oral route of administration as well as 
documented non-enzymatic cleavage of I3C into additional AhR ligands by gastric acid, 
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it is conceivable that higher concentrations of I3C and its newly formed metabolites are 
available within the gut (Benson et al. 2012a; Bjeldanes et al. 1991; Perdew et al. 2015). 
Recent advances in AhR biology further suggest that binding affinity and ligand 
metabolism may be better predictors of immunosuppressive outcome than ligand source 
(Boule et al. 2018a). Therefore, further analysis of I3C through a higher dose response as 
well as administration of purified metabolites would better evaluate I3C for effects on the 
thymus. Together, this is the first study to compare AhR activation by different types of 
compounds on thymocyte development and differentiation; thus, extending our 
knowledge of ligand-specific, AhR-mediated immunotoxic effects. 
Because we observed gross thymic atrophy with ITE, we more extensively 
characterized the ability of ITE to induce thymic atrophy.  Following previously 
published dosing regimens (Nugent et al. 2013; Quintana et al. 2010b), our data clearly 
demonstrate that daily administration of 8mg/kg ITE p.o. induced significant thymic 
atrophy in an AhR-dependent manner.  In addition, ITE induced noticeable decreases in 
both thymic weight and cellularity at doses as low as 1 mg/kg.  Moreover, 4m/kg ITE p.o. 
and 1mg/kg i.p. induced comparable levels of thymic atrophy in C57Bl/6 mice, 
demonstrating that ITE causes thymic atrophy regardless of the route of systemic 
exposure.  This point is particularly important given the growing interest in AhR research 
on identifying novel classes of potent, non-toxic AhR ligands for use in various 
therapeutic settings (Stockinger 2009). Moreover, these observations raise concerns about 
potential off-target immune toxicities associated with the use of ITE based immune 
therapies (Abron et al. 2018; Dolciami et al. 2018; Hao and Whitelaw 2013; Nugent et al. 
2013; Quintana et al. 2010c).  
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Multiple mechanisms for TCDD induced thymic hypocellularity have been 
suggested including reduced proliferation of DN precursor thymocytes (Lai et al. 1994), 
enhanced apoptosis at the DP stage (Camacho et al. 2005b), and enhanced emigration of 
thymocytes (Poland et al. 1994; Temchura et al. 2005), or a combination of these possible 
mechanisms. Apoptosis occurs normally during development and aging as a homeostatic 
mechanism to maintain cell populations in tissues, and as a defense mechanism when 
disease or noxious agents damage cells. Although apoptosis was reported to underlie 
TCDD-induced thymic atrophy (Kamath et al. 1998; Kamath et al. 1997), and thymic and 
peripheral T cells are highly sensitive to TCDD-induced apoptosis in vitro (Camacho et 
al. 2004), our work and that of others (Comment et al. 1992; De Heer et al. 1994; 
Silverstone et al. 1994a; Silverstone et al. 1994b; Staples et al. 1998) have failed to 
support this in vivo. In the current study, we investigated whether 10 g/kg TCDD 
initiates apoptosis in C57Bl/6 mice by quantifying the frequency and absolute number of 
apoptotic thymocytes by flow cytometry on day 7 post-exposure. Although TCDD-
induced thymic atrophy corresponded with an almost doubling of the frequency of 
Annexin V+7-AAD- apoptotic thymocytes compared to control animals, this did not 
correspond to a significant increase in the absolute number of apoptotic cells—likely due 
to the massive decline in overall thymus cellularity observed with exposure to TCDD. 
Earlier studies suggested that the timing and pathway of apoptosis was important to AhR-
mediated thymic atrophy (Kamath et al. 1998) and implied Fas-FasL interactions 
regulated apoptosis during TCDD-induced thymic atrophy (Camacho et al. 2005a). This 
led us to assess the mRNA expression of Fas and FasL using qRT-PCR on days 3, 7 and 
14 after administration of 10 g/kg TCDD in naïve wild-type C57Bl/6 mice, which did 
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not support TCDD-mediated induction of Fas and/or FasL gene expression in the thymus. 
Analysis of Fas and FasL protein expression by flow cytometry 3 days after 
administration of 10 g/kg TCDD to C57Bl/6 mice, further confirmed these results at the 
protein level.  
Because apoptotic cells may be rapidly cleared by phagocytic cells in vivo (Platt 
et al. 1998), we also probed the role of Fas-FasL interactions in TCDD-induced thymic 
atrophy using FasL-deficient (gld/gld) mice. In our studies, FasL-deficient (gld/gld) mice 
exposed to 10 g/kg TCDD experienced the same degree of thymic atrophy as Fas-FasL 
competent control mice and thymocyte subsets demonstrated no protection from TCDD-
induced alterations. Interestingly, assessment of an apoptosis and survival RT-PCR array 
yielded four genes which showed a significant increase in expression: BAD (7-fold 
change vs vehicle), Akt1 (4-fold change vs vehicle), and Pik3cd (2.5-fold change vs 
vehicle), Ppp3ca (2.5-fold change vs vehicle) in thymocytes on day 7 and no genes which 
were significantly reduced in expression. These data are consistent with evidence that 
suggests that apoptosis and survival genes in thymocytes are in constant flux. 
Collectively, our results fail to support Fas-FasL-mediated apoptosis as a mechanism of 
TCDD-induced thymic atrophy. These findings are in direct contrast to previously 
published reports, which implicated Fas-FasL interactions as playing an important role in 
TCDD-mediated induction of apoptosis and immunotoxicity (Camacho et al. 2002; 
Kamath et al. 1999b; Rhile et al. 1996).  In a majority of the previously reported in vivo 
studies, C57Bl/6 mice were exposed to 30-50 g/kg TCDD intraperitoneally (i.p.), and 
evaluated shortly thereafter, 6-24hrs, whereas in our study C57Bl/6 mice were exposed to 
10 ug/kg TCDD through oral gavage (p.o) and evaluated 3-14 days post-exposure. 
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Pharmacokinetics indicate that TCDD is more readily metabolized following p.o. than 
i.p. administration (Olson et al. 1980), thus we would expect that p.o. administration 
would yield lower bioavailability than i.p. delivery. These differences in dose and 
administration route may yield a substantially lower systemic TCDD concentration in our 
studies, and thus leads us to question whether exceedingly high concentrations of 
systemic TCDD initiate an immediate apoptotic response that does not last beyond the 
early time points tested by Camacho et al. (2005a). Supporting this, it was initially 
reported that thymocytes exhibit markers of apoptosis up until 24-hours post exposure 
(Camacho et al. 2005a); however, maximal thymic atrophy does not occur until 7-10 days 
post-exposure in adult mice (Silverstone et al. 1994a). Together, this may explain the 
difference in reports and suggests that apoptosis may be the most immediate, although 
not the most substantial mechanism, involved in thymic atrophy following exposure to 
lower concentrations of TCDD.   
Previous studies identified the AhR signaling pathway as the pivotal event in 
TCDD-induced thymic atrophy (Laiosa et al. 2003b; Staples et al. 1998) and the 
hematopoietic compartment as the target for TCDD-induced thymic atrophy (Staples et 
al. 1998).  However, until now, it was unclear which hematopoietically derived cell/s 
triggered TCDD-induced thymic atrophy.   To investigate the importance of cell-specific 
AhR signaling in TCDD-induced thymic atrophy, mice expressing the AhR floxed allele 
(AhRfx) were crossed to mice expressing Cre transgenes driven by LyzM (myeloid 
derived cells), CD11c (dendritic cells), RORt (DP and SP thymocytes), and FoxN1 
(thymic epithelial cells) specific promoters. Our results show for the first time that 
deletion of the AhR in CD11c+ dendritic cells prevents TCDD-induced thymic atrophy, a 
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previously unreported phenomenon. Therefore, the immunotoxic responses of TCDD on 
the thymus are dependent on AhR activation in CD11c+ dendritic cells. DCs make up a 
small percentage of the thymic stroma (Wu and Shortman 2005) and are located mainly 
in the medulla and corticomedullary region. Thymic DCs cross-present self-antigens to 
developing thymocytes, facilitate the generation of regulatory T cells, and act as 
gatekeepers of lymphocyte trafficking (Bonasio et al. 2006; Hubert et al. 2011; Lei et al. 
2011; Proietto et al. 2008b). DCs are thus poised to exert control over thymic output in 
response to environmental conditions. Unfortunately, the solubility limitations of ITE 
(~30 mg/mL DMSO) and I3C (~10 mg/mL in ethanol) prevent the use of either of these 
ligands in AhR conditional knockout mice at doses that would be expected to induce 
thymic atrophy.  Together, the current study significantly advances our understanding of 
how the AhR regulates immune responses and demonstrates for the first time that TCDD-
induced thymic atrophy occurs as a result of activation of the AhR in CD11c+ dendritic 
cells. Identification of CD11c+ dendritic cells as the direct target of TCDD-induced 
thymic atrophy offers insights into novel pathways to further understand the mechanisms 
of AhR-mediated immune regulation. Collectively, this work emphasizes the importance 
of research examining the contribution of cell- and tissue-specific consequences of 
chemical exposures on immune responses. 
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Chapter 2 Supplemental Figures 
 
Table 2. 1 Supplemental Mouse strains examined in this study 
   
Strain Common 
name 
Stock #  Relevant Phenotype(s) 
C57BL/6J C57BL/6 000664 Express the AhRb allele and are 
sensitive to TCDD-induced toxicity at 
10 µg/kg  
B6.D2N-Ahrd/J AhRd 002921 Express the AhRd allele and are 
sensitive to TCDD-induced toxicity at 
100 µg/kg  
B6Smn.C3-Faslgld/J  Gld 0010210 Unable to express functional Fas 
Ligand 
B6.129P2-
Lyz2tm1(cre)Ifo/J 
LyzMCre 004781 Allow for targeted deletion of the AhR 
in cells of the myeloid lineage: 
monocytes, mature macrophages, and 
granulocytes 
B6.Cg-Tg(Itgax-
cre)1-1Reiz/J 
CD11cCre 008068 Allow for targeted deletion of the AhR 
in cells of the dendritic lineage: 
conventional and plasmacytoid 
dendritic cells 
B6(Cg)-
Foxn1tm3(cre)Nrm/J 
Foxn1Cre 018448 Allow for targeted deletion of the AhR 
in thymic epithelial cells and 
keratinocytes. 
B6.FVB-Tg(Rorc-
cre)1Litt/J 
RORtCre 022791 Allow for targeted deletion of the AhR 
in DP thymocytes and their SP 
progeny. 
Ahrtm3.1Bra/J AhRflox 006203  Use to generate cell/tissue-specific 
mutants of the aryl-hydrocarbon 
receptor (AhR) 
 
 
 
 
 
 
Figure 2. 8 Supplemental Figure 1. AhRd mice are unresponsive to TCDD-induced thymic 
atrophy at 10 g/kg. 
 
 
Supplemental Figure 1. AhRd mice are unresponsive to TCDD-induced thymic atrophy at 10 
g/kg. Naïve wild-type mice (C57Bl/6) and mice expressing the low affinity receptor (AhRd 
mice) were gavaged with vehicle (anisole/peanut oil) or TCDD (10 or 100 µg/kg).   Three 
indicators of toxicity: body weight (data not shown), thymus weight (A), and thymus cell number 
(B) were measured on day 7 to evaluate toxicity and thymic atrophy after low dose (10 g/kg) 
and high dose (100 g/kg) of TCDD. Data represent one of two independent experiments, n=4-6 
per treatment group, mean + SEM; 2-way ANOVA, *p < 0.05 vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
vehicle
AhRd
C57Bl/6
10 µg/kg TCDD 
100 µg/kg TCDD 
C
D
4
 F
IT
C
CD8a PE-Cy7
13.9 + 2.4 40.3 + 8.5*
19.7 + 4.9 23.1 + 4.4 43.6 + 6.3*
8.3 + 1.4 19.7 + 2.6*
8.8 + 1.4 14.3 + 3.4 29.6 + 3.2*
75.3 + 3.3 30.2 + 6.9*
68.4 + 5.1 53.5 + 8.0 4.1 + 2.8*
2.3 + 0.4 9.5 + 1.5*
2.9 + 0.4 8.9 + 2.3 22.3 + 6.7*
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Figure 2. 9 Supplemental Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle 
and TCDD-exposed mice. 
 
 
Supplemental Figure 2. Comparison of CD4/CD8 thymocyte subsets from vehicle and 
TCDD-exposed mice. C57Bl/6 and AhRd mice were gavaged with vehicle (anisole/peanut 
oil) or TCDD (10 or 100 µg/kg).   Representative contour plots gating on live thymocytes 
from wild-type C57Bl/6 mice revealed a significant decline in the frequency of CD4+CD8+ DP 
thymocytes, as well as a relative enrichment in the percent of CD4-CD8- DN and CD4+CD8- 
and CD4-CD8+ SP thymocytes in 10 g/kg TCDD-treated mice compared to vehicle control 
on day 7.  These shifts in CD4/CD8 thymocyte subsets were not observed in AhRd mice 
treated with 10 g/kg TCDD but were observed following administration of 100 g/kg 
TCDD. The mean percentages of the CD4/CD8 thymocyte subsets + SEM are indicated in the 
plots. Data represent one of two independent experiments, n=4-6 per treatment group; 2-
way ANOVA, *p < 0.05 vehicle
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CHAPTER 3: DEVELOPMENT OF PEGYLATED LIPOSOMAL 
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Abstract 
 
 The AhR is a critical regulator of both innate and adaptive immune responses 
with potent immunomodulatory effects that make the AhR an attractive molecular target 
for novel therapeutics. Harnessing the immunosuppressive effects of AhR activation 
holds immense promise; however, the prototypical AhR ligand 2,3,78,8 tetracholoro-p-
dioxin, is highly toxic and not compatible for use in humans. Natural AhR ligands offer a 
safer alternative to TCDD, but barriers exist due to their rapid degradation, poor 
solubility, and high-dosing schemes. Packaging AhR agonists in liposomal nanoparticles, 
a biodegradable and biocompatible drug delivery system, offers an intriguing solution. 
Here, the thin film hydration method was used to develop Cy5-labelled PEGylated 
liposomal nanoparticles (LNP) loaded with the natural AhR ligand, 2-(1′H-indole-3′-
carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE). ITE entrapment efficiency was 
>90%, and LNP demonstrated long-term chemical and physical stability. LNP enabled 
steady release of ITE under physiological parameters with minimal drug escape or burst 
effect being observed. Murine bone marrow derived dendritic cells (BMDCs) cultured 
with LNP exhibit >85% cellular interaction efficiency with LNPs as measured by 
fluorescent cytometry and laser scanning cytometry.  LNP exposure does not reduce cell 
viability in vitro, and ITE-loaded LNP induce AhR responsive genes, including CYP1a1, 
TGFβ3, and IDO1/2. Furthermore, LNP administered intraperitoneally accumulated in 
the spleen with highest uptake occurring by splenic APCs. Collectively, these results 
demonstrate LNP delivery of AhR agonists as a promising mechanism for targeted, cell-
specific AhR activation.  
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Introduction 
  
 The Aryl hydrocarbon Receptor (AhR) is a potent immune-modulator and 
promising target for the treatment of autoimmune diseases, allergies, and chronic 
inflammatory disorders (Kerkvliet et al. 2009; Quintana et al. 2010a; Zhang et al. 2010). 
AhR activation by the high affinity ligand, 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD), 
results in pronounced immune suppression through the induction of suppressive immune 
cells including regulatory T cells (Tregs) and tolerogenic dendritic cells (DCs) (REF). 
However, TCDD is a highly toxic and persistent compound, which effectively eliminates 
its therapeutic use in humans (Needham et al. 1999). Numerous natural compounds 
generated endogenously and derived from plants, such as 2-(1H-Indol-3-ylcarbonyl)-4-
thiazolecarboxylic acid methyl ester (ITE), indirubin-3’-oxime (IO), and indole-3-
carbinol (I3C) can activate the AhR and can promote tolerogenic DCs and Tregs, 
providing favorable alternatives to TCDD for therapeutic AhR activation (Abron et al. 
2018; Benson et al. 2012a; Benson and Shepherd 2011b; Boule et al. 2018a; Ehrlich et al. 
2018; Singh et al. 2014). However, as AhR activation and natural agonists gain traction 
for pharmaceutical use, solutions are needed to overcome current barriers that reduce 
efficacy and practicality of natural ligands including poor solubility, rapid metabolism in 
vivo, and the requirement of frequent administration of high doses. 
 Numerous nanoparticle formulations are gaining traction as drug delivery 
systems. Liposomal nanoparticles (LNPs) are optimal biodegradable and biocompatible 
delivery systems to enhance therapeutic benefits, both in vitro and in vivo, and are 
considered to be the most successful drug-carrier system to date  (Bozzuto and Molinari 
2015; Kraft et al. 2014). LNPs have been shown to improve drug solubility and potency, 
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reduce off-target effects, protect drugs against metabolic degradation, and enable 
controlled drug release, which together, result in an increased therapeutic index 
(Akbarzadeh et al. 2013; Singh et al. 2014). Therefore, development of an ITE-loaded 
LNP could mitigate current obstacles associated with natural AhR agonist-based 
therapies and enable sustained, concentrated drug delivery to target tissues, while 
reducing adverse outcomes of systemic exposure and off-target effects. 
 Within the immune system, AhR expression varies significantly by cell type, 
maturation state, and activation status (Kreitinger et al. 2016). It is well documented that 
the effects of AhR activation during an immune response vary based on the target cell 
(Esser and Rannug 2015; Kreitinger et al. 2016; Stockinger et al. 2014) and that AhR 
activation can result in drastically different outcomes, from increasing inflammatory 
responses to promoting immune regulation or tolerance (Lee et al. 2015b). DCs, 
professional antigen-presenting cells that bridge the innate and adaptive immune system, 
constitutively express AhR at high levels and are keenly sensitive to AhR activation by 
multiple ligands (Bankoti et al. 2010a; Bankoti et al. 2010b; Kreitinger et al. 2016). AhR 
activation within DCs has been shown to induce a potent regulatory phenotype that 
promotes peripheral immune tolerance via induction of indoleamine-2,3-dioxygenase 
(IDO) and transforming growth factor beta (TGFβ)  isoforms, and generation of Tregs 
(Mezrich et al. 2010; Nguyen and Bradfield 2007; Simones and Shepherd 2011; Vogel et 
al. 2008). Together, DCs are an attractive focus for delivery of concentrated AhR 
agonists (Quintana et al. 2010c; Simones and Shepherd 2011).  
 In the present study, we aimed to develop fluorescently labeled, PEGylated ITE-
loaded LNPs using the thin film hydration method for delivery to dendritic cells. LNPs 
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were characterized for average particle size, long-term physical and chemical stability, 
and ITE entrapment efficiency. LNP uptake and drug delivery were evaluated in vitro 
through cultures with bone marrow derived dendritic cells (BMDCs), and in vivo 
biodistribution was assessed within lymphoid tissues following intraperitoneal 
administration.  Together, the results from this study support PEGylated LNPs as an 
effective ITE delivery system.  
 
Materials and Methods 
 
Chemicals 
 
 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt)  (DSPE- 
mPEG2000) were purchased from Avanti Polar Lipids, Inc (Alabaster, AL, USA). 
Cyanine5 NHS ester (Cy5) was obtained from Lumiprobe Corp., Hallandale Beach, FL, 
USA).  Cholesterol, chloroform (CHCl3), methanol (MeOH), triethylamine HPLC grade, 
and ethyl ether anhydrous ACS grade were purchased from Fisher scientific (Pittsburgh, 
PA, USA). 0.1M Phosphate Buffered Saline (PBS) pH 7.4, was purchased from EMD 
Millipore (Billerica, MA, USA).  2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid 
methyl ester (ITE) was purchased from Tocris (St Louis, MO, USA). Thin-layer 
chromatographic analyses were performed on Sigma-Aldrich 60 F254 thin-layer 
chromatographic plates. Column chromatography was performed with silica gel 230-400 
mesh. 1H NMR spectra were recorded on a Bruker Avance IIITM spectrometer at 400MHz 
and are reported in parts per million (ppm) on the δ scale relative to tetramethylsilane as 
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an internal standard. 13C NMR spectra were recorded at 100 or 125 MHz and are reported 
in parts per million (ppm) on the δ scale relative to CDCl3.Signals were abbreviated as 
follows: s = singlet, br s = broad singlet, d = doublet, t = triplet, q =quadruplet, m = 
multiplet. Coupling constants (J) are expressed in hertz. All solvents and chemicals used 
were reagent or analytical grade when not specified, and used as received.  
 
Procedure for the Preparation of Cy5-labelled DPPE 
 A previously published procedure was adapted to synthesize Cy5-NHS (Mizrahy 
et al. 2014). Cy5-NHS (12 mg, 0.019 mmol) was dissolved in 2 ml of DMF and 1 ml of 
CHCl3. Then, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE) (13.2 mg, 
0.019 mmol) was added followed by the addition of Et3N (2.6 µL, 0.019 mmol) (Figure 
1). The reaction mixture was heated to 70°C and stirred overnight. Upon completion, the 
solvent was removed under reduced pressure and the crude product was purified by 
column chromatography (length 15.5 cm;  diameter 15 cm) on silica gel (gradient 100, 
5:95, 10:90, 15:85 MeOH:DCM) to afford the Cy5–DPPE conjugate as a blue solid. Mass 
spectrometry spectra were obtained on a Waters/Micromass LCT-TOF instrument in 
methanol: M + H)+ 1156, purity>95%. 1H NMR (400 MHz, CDCl3/CD3OD: 2/1) δ 8.13 
(s, 1H), 8.06 – 7.86 (m, 1H), 7.43 (d, J = 7.2 Hz, 1H), 7.35 – 7.13 (m, 3H), 6.64 (t, J 
=12.5 Hz, 1H), 6.23 (dd, J = 18.4, 13.8 Hz, 2H), 5.37 (s, 1H), 5.24 (s, 1H), 4.43 (d, J = 
11.9 Hz, 1H), 4.20 (dd, J = 12.0, 6.7 Hz, 1H), 4.14 – 3.90 (m, 8H), 3.62 (s, 3H), 3.44 (s, 
4H), 2.42 – 2.23 (m, 4H), 1.83 (d, J = 6.8 Hz, 2H), 1.74 (s, 8H), 1.52 (d, J = 7.3 Hz, 2H), 
1.26 (s,48H), 0.88 (t, J = 6.1 Hz, 6H). Rf of Cy5-DPPE: 0.6 in 10/90 
methanol:dichloromethane. 
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Figure 3. 1 Preparation of Cy5-labelled DPPE 
 
Figure 3.1 Preparation of Cy5-labelled DPPE 
Schematic of fluorescent molecule, Cy5-NHS, added to 1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine (DPPE) for incorporation into, and tracking of, liposomal 
nanoparticles. 
 
 
 
Preparation of Liposomal nanoparticles (LNPs) by lipid film hydration  
 
 The lipid mixture (0.85 mM) composed of DSPC: cholesterol: DSPE-mPEG2000: 
Cy5-DPPE at a molar ratio of 59:34:5:2 was dissolved in a chloroform:methanol mixture  
(2:1, vol/vol) in a round bottom flask. 1 µM ITE stock solution in DMSO was added to 
the lipid mixture and the resulting solution was dried to a thin and transparent film using 
a rotary evaporator (Buchi Rotavapor R-215, Switzerland) under reduced pressure 
(Bangham et al. 1974). Multilamellar vesicles (MLVs) were obtained by hydration of the 
film with PBS (pH 7.4). After five cycles of freezing and thawing, the liposome diameter 
was reduced by ultrasonication with a probe sonicator (MISONIX Microson™r XL2000, 
Farmingdale, NY, USA) and samples filtered through PFTE syringe filter, 0.2 µm, to 
remove the titanium fragments. ITE-loaded liposomal nanoparticles (ITE-LNPs), non-
fluorescent and fluorescent empty liposomal nanoparticles were prepared following the 
steps described above. All the LNPs were stored at 4°C prior to analysis and experiments. 
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MLVs lyophilization and rehydration 
 The MLVs were prepared as above. Polysorbate 20 (5% of total lipids weight) or 
trehalose (4:1 lipids ratio) was added to the MLVs suspension and stirred at 65°C 
immediately after the freezing and thawing cycles. The MLVs suspension was frozen at -
80°C and then lyophilized using a Labconco Dry Ice Benchtop Freeze Drying System 
(Kansas City, MO, USA). The resulting powder was stored at 4°C and rehydrated at 
different time points with PBS (pH 7.4) to its original volume. The liposome diameter 
was reduced by ultrasonication with a probe sonicator (MISONIX Microson™r XL2000, 
Farmingdale, NY, USA) and filtered through PFTE syringe filter, 0.2 µm, to remove the 
titanium fragment. The SUVs were stored at 4°C prior to analysis. 
 
Morphological studies  
 Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) 
were used to characterize the surface and structure of ITE-loaded LNP samples, 
respectively.  Samples prepared for TEM were placed on single slot formvar-coated 400 
mesh copper grids. Excess sample was blotted off with filter paper, and the grid was then 
stained with 1% phosphotungstic acid solution for 1 minute. Stain was blotted dry from 
the grids with filter paper and air-dried. Samples were imaged with a Hitachi H-7100 
TEM (Hitachi, Tarrytown, NY, USA) at 75kV. ITE-loaded LNP samples prepared for 
SEM were placed on a 0.1 um pore PVDF filter and allowed to air dry. Dried LNP 
samples were placed on a non-conductive carbon adhesive tape applied on aluminum stub 
and coated with gold using a Denton Desk V sputter coater (Denton Vacuum LLV, 
Moorestown, NJ). Samples were imaged using a Hitachi S-4700 Field Emission scanning 
electron microscope 
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Size distribution and surface potential measurements 
 
 Mean diameter, size- distribution, polydispersity index (PDI) and zeta potential of 
the LNPs were determined at 25°C by dynamic light scattering (DLS) using a Zetasizer 
nano ZS (Malvern Intruments Ltd, Malvern, UK). Samples were analyzed 24H after 
preparation and three measurements were taken on each sample. 
 
Determination of ITE entrapment efficiency 
 The entrapment efficiency for ITE was determined using a Waters HPLC Alliance 
system on an e2695 separations module with a Waters 2998 photo-diode array (PDA) 
detector (Milford, MA, USA). Samples were injected using a Waters auto injector and the 
instrument was controlled by use of MassLynx™ software (Milford, MA, USA). 
Components were separated on a Waters Phenomenex ™ C18 reversed-phase column 
(Milford, MA, USA) with 50 x 4.6 mm dimensions and 3 μm particle size. The column 
was kept thermostatic at 30°C in a Waters column oven (Milford, MA, USA). HPLC 
baseline resolution was obtained by employing a gradient elution at a flow rate of 0.3 
ml/min with a gradient mobile phase composed of methanol (0.1% formic acid) (B) and 
water (0.1% formic acid)(A) ramped over a 12 minute period using the following 
conditions: and monitored at 360 nm as follows: The binary linear gradient began from a 
mixture of 10% A and 90% B and ended at 2% A and 98% B at 6.60min.  After the 1.40 
min. plateau at 2% A and 98% B, the mobile phase composition changed back to its 
initial composition starting at 8 min. in 4 min. The ITE entrapment efficiency in LNPs 
was expressed as entrapment percentage (EE%) and calculated through the following 
relationship: EE% =  (Ctotal  – Cfree)/ Ctotal] X 100. The free drug (Cfree) was separated by 
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pressure ultrafiltration method using an Amicon 8010 (Millipore Corporation, bedford, 
USA) at 50psi and determined by the LC/MS method described above. The total content 
of ITE (Ctotal )in the suspensions was determined after  the ITE-loaded LNPs suspensions 
were frozen at -80°C and then lyophilized using a Labconco Dry Ice Benchtop Freeze 
Drying System (Kansas City, MO, USA). The ITE-loaded LNP powders were then 
diluted with methanol to disrupt the LNPs, release the entrapped drug into the solvent and 
to afford the LC/MS injectate solution. Peaks of products were monitored using the 
LC/MS method described above. The concentrations of ITE were determined using a 
calibration curve of the pure drugs in methanol solutions at the wavelength where it 
showed maximum absorbance (360 nm). The area under the curve was converted into 
percentage using a standard curve, and experiments were performed in triplicate in order 
to ensure accuracy. 
Stability study of ITE-loaded LNPs 
 The stability of the ITE-loaded LNPs in suspension and lyophilized form was 
evaluated initially and after storage at +4°C for three months. The particle size 
distribution, the polydispersity index and the total drug content of the samples were 
determined as a function of the storage time. 
In vitro release kinetics 
 ITE release from LNPs was studied using a dialysis method. Dialysis cassettes 
(Slide-A-Lyzer Dialysis Cassettes 10K MWCO, Thermo Fisher Scientific, Waltham, 
MA, USA) were immersed before use in ultrapure water overnight at 4°C to remove the 
preservative, followed by rinsing in PBS (pH 7.4) solution. 1 mL of ITE-loaded LNPs 
suspension (0.3μg ITE) was injected into the dialysis cassette and dialyzed at 37°C 
 
 87
against 100 mL of PBS (pH 7.4). The sink conditions may permit the free ITE released 
from the LNPs to migrate through the dialysis membrane without precipitating as the 
solubility of ITE has been calculated to be 0.05mg/mL (ChemAxon Aqueous Solubility 
Predictor - Version 16.3.14.0) in PBS (pH 7.4). At various time points (0-120H), 20 mL 
aliquots of the release buffer were withdrawn for analysis and replaced by 20 mL of fresh 
release medium. The samples were lyophilized and stored at 4°C until analysis. The 
amount of drug released was quantified using the LC/MS method described above. Drug 
release profile from LNPs was expressed as release percentage (RP%) and calculated 
through the following relationship: %RP= [Creleasel / Ctotal] X 100. Where Crelease is the 
amount of ITE released at a specific time and Ctotal is the total amount of ITE in LNPs. 
Thermal analysis 
 DSC analysis of the lyophilized empty and ITE-loaded LNPs was performed 
using a TA instruments Q10 model (TA Instruments, New Castle, DE, USA). Calibration 
of the instrument was done using Indium for the best heat capacity at constant pressure 
(Cp) estimate and high signal-to-noise ratio. Two mg of lyophilized LNPs samples were 
loaded in hermetically sealed aluminum pans along with the standard reference aluminum 
in the differential scanning calorimeter. The DSC was recorded between 10°C and 90°C 
at a scan rate of 1°C/min for three cycles and the last reproducible heating cycle was 
considered for analysis. 
 
Mice 
 C57Bl/6 mice were originally obtained from The Jackson Laboratories (Bar 
Harbor, ME) and were bred and maintained in the animal research facilities at the 
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University of Montana. Mice were housed under specific pathogen-free conditions and 
maintained on 12 h dark/light cycles. Standard laboratory food and water were provided 
ad libitum. All protocols for the use of animals were approved by the University of 
Montana Institutional Animal Care and Use Committee and adhered to the current 
National Institutes of Health (NIH) guidelines for animal usage. 
 
Bone Marrow Derived Dendritic Cell (BMDC) Cultures 
 
 Cellular uptake assays were performed using Bone Marrow Derived Dendritic 
Cells (BMDCs). BMDCs were generated from 7-day cultures of bone marrow-derived 
progenitor cells from femurs and tibias of C57Bl/6 mice (Bankoti et al., 2010). Briefly, 
hematopoietic progenitor cells were collected by flushing murine femurs and tibias with 
complete RMPI media (cRPMI) (Gibco, Grand Island, NY) supplemented with 10% fetal 
bovine serum (Atlanta Biologicals, Atlanta, GA), 50µM 2-mercaptoethanol, 20mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid, 10mM sodium pyruvate, and 50 µg/ml 
gentamicin (Gibco, Grand Island, NY) (Corning, Manassas, VA). Red blood cells were 
removed through density gradient centrifugation using Lympholyte-M reagent (Cedarlane 
Laboratories Limited, Ontario, Canada). Isolated hematopoietic precursors were then 
cultured at a density of 1x106 cells/ml in T75 tissue culture flasks for 7 days at 37°C and 
5% CO2 in the presence of 30 ng/ml murine granulocyte macrophage-colony stimulating 
factor (GM-CSF) (PeproTech, Rocky Hill, NJ). cRPMI and GM-CSF growth factor were 
refreshed on days 3 and 5. On day 7, nonadherent cells were harvested and BMDC purity 
was verified via fluorescence cytometry. BMDCs were then re-cultured in 6-well plates 
with LNPs at 10-1,10-2,10-3 to yield ITE-loaded LNP concentrations [100nM, 10nM, 1nM 
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respectively] for 24-96 hours or with 10nM 2,3,7,8, tetrachlorodibenzo-p-dioxin (dioxin, 
TCDD) in DMSO (Cambridge, MA). 
 
Dye exclusion viability assays 
 
 To assess effects of LNP uptake on cell viability, cultured cells were treated with 
optimum titrations of propidium iodide (PI) nucleic acid stain (Sigma-Aldrich) as a 
membrane exclusion assay via fluorescence cytometry. As a control for dead or dying 
cells, 1x106 BMDCs were incubated at 55°C for >10-minutes and then stained with PI as 
described above.  
 
In vivo LNP exposure 
 
 Naïve, adult (8-14 week-old) C57Bl/6 mice received 10uL LNP/gram body 
weight or PBS control via intraperitoneal injection (i.p.) daily for three consecutive days. 
Mice were weighed daily and tissues were collected 24 hours after the last injection. 
Following CO2 euthanasia, blood was collected through cardiac puncture in EDTA (0.5 
M) coated syringes. Tissues were collected and processed through 70μM cell strainers in 
cRPMI and maintained on ice prior to downstream assays. 
 
Fluorescence cytometry 
 
 Fluorescence cytometry to assess cellular uptake of Cy5-labeled LNPs was 
performed using a FACS Aria II flow cytometer (v 6.1.2, Becton Dickinson, Franklin Lakes, 
NJ) or Attune NxT Acoustic Focusing Flow Cytometer (Thermo Fisher Scientific, 
Waltham, MA). Cells were harvested and washed with PAB (1% bovine serum albumin 
and 0.1% sodium azide in PBS), followed by a 10-minute incubation with anti-
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CD16/CD32 Fc Block (BioLegend, San Diego, CA) to eliminate non-specific staining 
(Shepherd et al., 2001). Antibodies used in these experiments included CD11c-PE (HL3 
and N418), F4/80-BV421 (BM8), CD11b-PE-Dazzle594 (M1/70), CD3-Percp/Cy5.5 
(145-2C11), CD19-FITC (MB19-1), MHCII-FITC (M5/114.15.2), and CD86-BV510 
(GL-1), and were obtained from Biolegend (San Diego, CA), Tonbo (San Diego, CA), 
and BD Biosciences (San Jose, CA). All staining was performed at optimized titrations 
for 20 minutes, on ice, and protected from light. To control for spectral spreading and 
autofluorescence by the LNPs, control samples were treated with empty liposomes 
lacking Cy5. Fluorescence Minus One (FMO) controls were used for gating controls. 
BDCompBeads (BD Biosciences, San Jose, CA) compensation beads were used for 
compensation controls.  
 
Fluorescence microscopy 
 
 Laser scanning cytometry (LSC/iCys, CompuCyte, Cambridge, MA) was used to 
corroborate cellular interaction with Cy5+ LNPs. Cells were adhered to glass slides using 
the Cytospin 3 (Thermo Fisher Scientific, Waltham, MA) at a concentration of 1x105 
cells/slide.  Cells were stained with diamidino-2-phenylindole (DAPI) nuclear stain 
(Thermo Fisher Scientific, Waltham, MA) and treated with Prolong Gold Antifade 
Mountant (Thermo Fisher Scientific, Waltham, MA) prior to cover slide placement. iCys 
CompuCyte software (Cambridge, MA) was used for obtaining images and calculating 
fluorescence intensity of samples. Cells exposed to unlabeled (Cy5-), empty LNPs were 
used as controls for autofluorescence. 
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RNA isolation and RT-qPCR 
 Total RNA was extracted from 5 x 106 BMDCs using a RNeasy mini kit (Qiagen, 
Germantown, MD) according to the manufacturer protocols. Two-step RT-qPCR was 
performed by synthesizing cDNA using iScript Reverse Transcription Supermix (BioRad, 
Hercules, CA) followed by RT-qPCR relative quantification of 50 ng cDNA per reaction 
using CFX Connect, SSO Advanced Universal SYBR Green Master Mix, and PrimePCR 
validated primers for murine CYP1A1, IDO1, IDO2, TGFΒ3 (BioRad, Hercules, CA). 
The data were normalized to the reference genes, GAPDH and HPRT, and displayed 
relative to control.  
 
Statistical analyses 
 Data sets with multiple comparisons were evaluated by one-way analysis of 
variance (ANOVA) followed by post-hoc analysis using student’s t-test. Values of 
p<0.05 were considered significant. 
 
Results 
 
LNPs are optimally sized, demonstrate high ITE entrapment efficiency, and maintain 
long-term stability. 
 
 Nanocarrier size has been established as a crucial determinant for optimal cellular 
delivery and should not exceed 500 nm (Olsen et al. 2011). Studies by Foged et al. 
demonstrated that limiting NP size to 100 nm resulted in twice the cellular uptake 
compared to larger NP (Foged et al. 2004); however, further reduction in size to 40nm 
did not increase cellular uptake. Particle size analysis established that the average size of 
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both freshly prepared and lyophilized PEGylated ITE-loaded LNPs was within the 
optimal range, ~100 nm, with a unimodal size distribution, and a low polydispersity 
index ≤0.2 (Figure 3.2a). The addition of Polysorbate 20 enabled median particle size of 
lyophilized LNP to be comparable to fresh LNP through a shortened rehydration step (< 
5min). To evaluate LNP morphology, SEM and TEM of ITE-loaded LNP were 
performed. As modeled in Figure 3.2b, the ITE-loaded LNP should be composed of two 
lipid layers with an aqueous core. Representative SEM and TEM images, shown in 
Figure 3.2c and 3.2d, confirmed that ITE-loaded LNPs were spherical in shape, 
maintained an aqueous core, and were in the same nanosize range as observed from DLS 
measurements. 
 Previous studies have shown that high encapsulation efficiency of lipophilic drugs 
and almost no drug loss can be achieved using the lipid film hydration method (Çağdaş et 
al. 2014; Jesorka and Orwar 2008) ITE entrapment efficiency was greater than 70% for 
freshly prepared and lyophilized PEGylated LNPs at both 1nM (data not shown) and 
1µM ITE loading (Figure 3.3a). Compared to lyophilized LNPs, dramatically higher 
entrapment efficiency was observed for the non-lyophilized LNPs, 72% and 94% 
respectively. As expected, a reciprocal relationship occurred between LNP ITE loading 
and free ITE concentrations with a higher level of free ITE detected in lyophilized LNP 
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Figure 3. 2 Morphology and Characterization of ITE-loaded LNPs. 
 
 
 
 
 
 
 
 
 
Figure 3.2  Morphology and Characterization of ITE-loaded LNPs. 
Freshly prepared and lyophilized 1μM ITE-loaded PEGylated LNP were evaluated for 
hydrodynamic diameter (nm), polydispersity, and z-Potential (mV) (A).  LNP morphology 
diagram depicting round morphology and ITE interaction with the lipid bilayer (B). 
Representative images of morphology studies of ITE-loaded LNP through Transmission 
Electron Microscopy  micrograph (magnification X150000) (C) and Scanning Electron 
Microscopy micrograph (magnification X150000) (D). 
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(15.7%±2.1) compared to fresh LNP (2.2%±1.2); however, minimal ITE remained free in 
either preparation. Together, these results confirm that freshly formulated and lyophilized 
LNPs can be efficiently loaded with ITE and adopt an optimal size and morphology for 
cellular uptake. 
 The effects of storage conditions on LNPs were evaluated because chemical and 
physical stability over longer time periods is desirable for pharmaceutical applications. 
Following synthesis, ITE-loaded LNPs were stored at 4°C for three months to assess 
long-term chemical stability. As shown in Figure 3.3b, at 15 days and two months post-
synthesis, there was no significant decrease in total drug loading in either fresh or 
lyophilized LNP; however by three months a slight, statistically significant, decrease in 
drug loading was observed in the lyophilized LNP (79%) compared to fresh LNP (85%).  
Despite the slight decrease observed in total drug loading by month three, no degradation 
product was identified, and stored LNPs elicited the same level of gene expression 
(CYP1A1) as fresh LNP when tested in vitro (data not shown). Additionally, LNPs 
showed high physical stability over three months whether stored at 4°C as an aqueous 
colloidal suspension or rehydrated in PBS (pH 7.4) from the lyophilized cake. As shown 
in Figure 3.3c, long-term storage did not significantly alter polydispersity of fresh LNP  
(0.22 ± 0.02) or lyophilized LNP (0.15 ± 0.01) and mean diameters were equally 
maintained in both fresh LNP (115.7nm ± 1.9) and lyophilized LNP (97.9nm ± 0.3). 
Thus, both freshly prepared and lyophilized LNP demonstrate physical and chemical 
stability over three months at 4°C. 
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Figure 3. 3 Chemical and physical stability of ITE-loaded LNP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Chemical and physical stability of ITE-loaded LNP 
Total ITE content and free ITE of LNP was determined using HPLC  and calculated as  EE% 
= (Ctotal  – Cfree)/ Ctotal] X 100 (A). Long term ITE entrapment was evaluated in LNP stored at 
4°C for 15 days, 30 days, and 90 days prior to HPLC analysis (n=3) (B).  Physical stability of 
LNP was assessed for both  fresh and lyophilized LNP at 90 days (C).  
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ITE interacts with lipid bilayers of the LNP following drug loading and is released within 
24-hours in vitro 
 
 ITE is a highly lipophilic compound due to its planar, aromatic structure, and 
LNPs were observed to contain an aqueous core, together suggesting ITE containment is 
occurring by the LNP lipid bilayer. To confirm this, differential scanning calorimetry  
(DSC) thermograms of empty and ITE-loaded LNPs were performed. As shown in Figure 
3.4, endothermic peaks of the phase transitions from a gel phase to a liquid crystalline 
(Tm) phase were observed for both empty and ITE-loaded LNPs. The empty LNP 
thermogram showed a broad endotherm at 34.09°C corresponding to lipid bilayer 
components. The melting endotherm of the lipid bilayer components was found to be 
shifted to 43.32°C, suggesting interaction of ITE with lipid bilayers (Hathout et al. 2007) 
and successful drug encapsulation.  In addition, enthalpy changes (δHcal) reflect the 
differences in the packing properties of the acyl chains(Sade et al. 2010; Serro et al. 
2014). As seen in Figure 3.4., δHcal increased from 0.06 J/g for the empty LNPs to 0.19 
J/g for the ITE-loaded LNPs, which may indicate a more densly packed LNP membrane 
following ITE loading.(Maswadeh et al. 2002; Sade et al. 2010).  
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Figure 3. 4 Differential scanning calorimetry (DSC) thermograms of empty and 
ITE-loaded LNPs 
 
 
 
 
 
 
 
Figure 3.4 Differential scanning calorimetry (DSC) thermograms of empty and ITE-
loaded LNPs. The DSC was recorded between 10°C and 90°C at a scan rate of 1°C/min 
for three cycles and the last reproducible heating cycle was considered for analysis. 
Endorthermic peaks of empty LNP (solid) and ITE-loaded LNP (dashed) are shown.   
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 Previous studies have shown that uptake of nanoparticles in the size range of 100-
200 nm by dendritic cells can occur at a relatively fast rate, within 1 to 2 hours of in vitro 
exposure at 37°C (Kochiadakis et al. 2001; Tacken et al. 2011; Tran et al. 2018). To 
evaluate the rapidity of ITE release from LNPs in vitro, LNPs were incubated at 37°C 
against 100-fold excess PBS (pH 7.4) under dialysis conditions for 120 hours (5 days) 
and the cumulative percentage of ITE release was plotted versus time (Figure 3.5). A 
sustained-release effect was observed for ITE as only 14% of the drug was released from 
the LNPs in the first thirty minutes. The drug release profile fit a first kinetic order 
release phase in the first 4 hours and then approached a plateau at 24 hours.  
Approximately 50% of the total ITE dose was released within two hours in vitro and 90% 
release observed by 24 hours. The plateau value represented ~95% release of total 
incorporated drug and only ~3 % of the drug was still associated with the LNPs by day 5. 
Thus, LNPs release ITE rapidly and completely in vitro.  
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Figure 3. 5 In vitro ITE release curve from ITE-loaded LNPs under physiological 
conditions. 
Figure 3.5 In vitro ITE release curve from ITE-loaded LNPs under physiological conditions.
Dialysis of LNP at pH7.4 and 37°C to represent physiological conditions. Cumulative ITE  
drug release was quantified by LC/MS over 100 hours where %= [Creleasel / Ctotal] X 100. 
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Drug-loaded LNPs demonstrate increased uptake by BMDCs without affecting cell 
viability.  
 
 Liposomal formulations are highly promising therapeutic delivery systems as 
studies have demonstrated that LNPs are both biodegradable and biocompatible. To test 
potential cytotoxicity of LNPs on target cells, murine BMDCs were generated and 
exposed to three doses of empty LNP (ten-fold serial dilution of LNP:media 10-1,10-2,10-
3) for 24 or 96 hours. BMDC LNP uptake efficiency was evaluated for dose and time-
dependent effects by measuring Cy5+ CD11c+ BMDCs via fluorescent cytometry. As 
shown in Figure 3.6a, dose-dependent effects were observed at both time points as 
BMDCs exposed to 10-1 LNP exhibited the highest frequency of Cy5+ (24H-
85.2%±0.78) compared to 10-2 LNP (24H-73%± 1.0) and 10-3 LNP (24H-44%±1.3).  
LNP uptake occurred most rapidly and completely at high LNP concentrations with 
greater time required for LNP uptake at lower concentrations. BMDCs were then stained 
with propidium iodide (PI), a DNA intercalating agent that is unable to permeate healthy 
cell membranes, for analysis of cell viability by fluorescence cytometry.  As shown in 
Figure 3.6b, compared to untreated cells, LNP exposure did not reduce BMDC viability 
at any concentration following either 24-hour exposure (~86% viable) or 96-hour 
exposure (~75% viable). Thus, LNPs interact with BMDCs rapidly and do not reduce cell 
viability. 
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Figure 3. 6 LNP interaction is dose and time dependent and does not reduce BMDC 
viability. 
 
 
Figure 3.6 LNP interaction is dose and time dependent and does not reduce BMDC viability. 
Day 7 BMDCs were cultured with three concentration of LNP and interaction efficiency was 
calculated as IE=[%LNP+CD11c+ cells/Total CD11c+ cells]x100 (A). Cell viability was evaluated 
by propidium iodide nuclear staining and measured via fluorescence cytometry. n=3 with SD. 
*p<0.05 comparing LNP concentration within a single time point. # p<0.05 comparing time points 
with same LNP concentrations. 
 
 102
 Because differences in LNP stability were observed following drug loading, 
BMDCs were cultured with 10-1 empty or ITE-loaded LNP for 24 hours and cells were 
imaged using iCys laser-scanning cytometry.  Representative iCys images, Figure 3.7a, 
show that BMDCs cultured with ITE-loaded LNP exhibited higher LNP density per cell 
(MFI = 1.52 x 106) than BMDCs cultured with empty LNP (MFI = 1.43 x 106). 
Fluorescence cytometry corroborated iCys imaging as BMDCs cultured with ITE-loaded 
LNP, compared to empty LNP, displayed significantly greater LNP+ frequency (ITE-
loaded 91.0%±0.2, empty LNP 85%± 1.0) and density (ITE-loaded 4,159.0 ± 80.0, empty 
LNP 3,676.3 ± 107.7), as shown in Figure 3.7b. Empty LNP exposure in the presence of 
ITE that was added directly to culturing medium did not lead to increased LNP uptake 
(data not shown). Interestingly, mature BMDCs (CD11c+ MHCII high) exhibited greater 
uptake of ITE-loaded LNP compared to immature BMDCS (CD11c+ MHCII low), and 
non-BMDC (CD11c-MHCII-), as shown in Figure 3.8. Together, ITE-loading of LNP 
resulted in increased LNP uptake by BMDCs with preferential acquisition by mature 
BMDCs. 
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Figure 3. 7 ITE-loaded LNP display increased uptake by BMDCs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 ITE-loaded LNP display increased uptake by BMDCs.  
Day 7 BMDCs were cultured with ITE-loaded and empty LNP for 24 hours and LNP uptake was 
assessed by laser scanning cytometry (A) and fluorescence cytometry (B).  Nuclei are labeled 
with DAPI (blue) and LNP with Cy5 (red) in representative iCys images. n=3 per treatment  
* p<0.05 between ITE loaded and empty LNP. 
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Figure 3. 8 LNP uptake is BMDC maturation state-dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 LNP uptake is BMDC maturation state-dependent.  
BMDCs were exposed to ITE-loaded LNP (10-1) for 24hrs and analyzed by fluorescence 
cytometry.  LNP uptake after 24hrs was evaluated by BMDC maturation state where 
CD11c+MCHIIhigh denote mature BMDCs (Red), CD11c+MHCIILow denote immature BMDCs 
(Blue), and CD11c-MHCII- denote non-DCs (orange) and cell only control (Gray). 
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ITE-loaded LNPs induce expression of AhR-responsive genes in BMDCs. 
 Dendritic cells display altered gene expression following TCDD-induced AhR 
activation that is associated with tolerogenic or regulatory DC function (Bankoti et al. 
2010a; Bankoti et al. 2010b; Jin et al. 2010; Quintana et al. 2010a; Simones and Shepherd 
2011; Takenaka and Quintana 2017; Vorderstrasse and Kerkvliet 2001). Therefore, to 
evaluate whether ITE-loaded LNP delivered the drug cargo to BMDCs and activated the 
AhR resulting in gene expression similar to TCDD, BMDCs were exposed to 10-1 ITE-
loaded LNP [100nM ITE], to 10-1 empty LNP with ITE [100nM] added directly to 
culturing medium, or to TCDD [10nM]. Following 24-hour exposure, gene expression 
was measured by RT-qPCR. As shown in Figure 9, compared to untreated BMDC 
controls, the prototypical target gene induced by AhR activation, CYP1a1, was induced 
equally in BMDCs exposed to TCDD (25-fold) and ITE-loaded LNPs (25-fold induction 
vs control, respectively) while empty LNPs with ITE added exogenously to culture media 
resulted in significantly less CYP1a1 induction (10-fold vs control). While IDO1 
transcription was not significantly altered by any treatment group, IDO2 was 
substantially upregulated in all treatments groups with greatest induction observed 
following treatment with ITE-loaded LNP (TCDD: 7-fold; Empty LNP+ ITE: 8-fold; ITE 
Loaded LNP: 36-fold). TGFβ3 was not significantly upregulated by any treatment other 
than ITE-loaded LNP (9-fold).  Together, these data support that ITE-loaded LNP 
delivered ITE cargo to dendritic cells resulting in the upregulation of previously defined 
AhR-inducible immunoregulatory genes.  
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Figure 3. 9 ITE-Loaded LNP exposure leads to increased gene expression consistent 
with AhR activation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9 ITE-Loaded LNP exposure leads to increased gene expression consistent with AhR 
activation.  Day 7 BMDCs were exposed to TCDD, Empty LNP with externally added ITE 
(100nM), and ITE-loaded LNPs (10-1) or left untreated for 24hrs. mRNA expression was assessed 
via RT-qPCR analysis. Fold change is relative to cell only control and all genes are normalized to 
β-actin reference gene. Genes analyzed include: cytochrome P450, family 1, subfamily a, 
polypeptide 1 (Cyp1a1), indoleamine-2,3-dioxygenase 1 (IDO1), indoleamine-2,3-dioxygenase 2 
(IDO2), transforming growth factor, beta 2 (Tgfb2). Data shown are representative of two 
experiments  (n=3). Asterisks indicate significance of p≤0.05. 
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In vivo administration of ITE-loaded LNP results in their preferential deposition in the 
spleen and acquisition by APCs. 
  
 To assess biodistribution of ITE-loaded LNP within lymphoid tissues in vivo, 
C57Bl/6 mice received daily intraperitoneal injections (10uL/g/bw) for three consecutive 
days. Single cell suspensions of spleen, mesenteric and popliteal lymph nodes, as well as 
PBMCs were evaluated for LNP deposition by fluorescence cytometry. As shown in 
Figure 10, LNP were not detected in blood or lymph nodes, however, LNP were present 
in the spleen with twenty percent of live splenocytes having acquired LNP. Immune cell 
populations of the spleen were then evaluated individually to determine subset-specific 
LNP uptake. Antigen presenting cells, including macrophages and dendritic cells, 
exhibited the highest LNP interaction with 43% of macrophage and 48% of DCs being 
LNP+, while B cells and T cells had lower uptake frequencies at 22% and 15%, 
respectively.  Additionally, the evaluation of LNP density per cell, measured by mean 
fluorescence intensity (MFI), established that DCs and macrophage acquired 1.5 times 
more LNP  (1500 MFI) than B cells (1000 MFI) and 3 times more LNP than T cells (500 
MFI). Together, splenic APCs preferentially, but not exclusively, acquire LNPs following 
in vivo intraperitoneal administration. 
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Figure 3. 10 Splenic APCs preferentially take up LNPs in vivo following i.p. 
administration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Splenic APCs preferentially take up LNPs in vivo following i.p. administration. 
C57Bl/6 mice were treated i.p. with LNP at 10μl/kg/bw daily for three days and tissues were analyzed 
for Cy5+ expression via fluorescence cytometry (A). The percent of LNP+ splenic immune cells was 
evaluated as  frequency and mean fluorescence intensity (MFI).  
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Discussion 
 
 Activation of the AhR signaling pathway results in potent immunomodulatory 
outcomes and is a highly promising target for treatment of immune-mediated 
inflammatory diseases. Given that the prototypical AhR agonist, TCDD, is highly toxic, 
non-toxic AhR ligands are of keen interest for therapeutic activation of the AhR.  Non-
toxic compounds, such as ITE, can be potent AhR activators; however, barriers currently 
exist in the rapid metabolism and high dosing requirements necessary for biological 
effects. Therefore, this study investigated the potential for ITE as a proxy for natural AhR 
ligands, to be packaged and delivered using a PEGylated LNP carrier. 
 Numerous factors must be considered when determining drug delivery systems 
for biological use. Importantly, the size of particle can substantially affect toxicity and 
pharmacokinetics. Small particles are more reactive and toxic due to greater surface area 
and are more likely to undergo renal clearance than larger particles (Albanese et al. 
2012). Conversely, if particles are too large, they are quickly opsonized and cleared by 
the mononuclear phagocyte system (Albanese et al. 2012). A combination of PEGylation 
and maintaining a hydrodynamic diameter <100nm should provide optimal 
pharmacokinetic properties with minimal toxicity.  We demonstrated that both 
lyophilized and fresh PEGylated LNP maintained hydrodynamic ranges within the 
optimal size of 100nm and were of spherical shape. While freeze-drying can result in 
increased particle size compared to fresh LNP, the addition of Polysorbate 20 enabled 
comparable size retention, likely by preventing vesicle aggregation that can occur 
following lyophilization (Nohara et al. 2009). Maintaining optimal size of LNP following 
freeze-drying is important because lyophilization is considered a highly relevant method 
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to extend the shelf life of LNPs and drugs. Overall, the size and morphology of fresh and 
lyophilized LNP suggests that these nanoparticles are highly suitable for biological 
applications. 
 ITE is a very effective AhR activator; however, lower binding affinity and 
increased metabolism require higher concentrations and more frequent administration for 
effects similar to TCDD, the prototypical AhR ligand (Abron et al. 2018; Ehrlich et al. 
2018; Henry et al. 2010; Quintana et al. 2010a). Therefore, we determined the efficiency 
of ITE entrapment and release from LNP. Both fresh and lyophilized LNP exhibited high 
entrapment efficiencies with a slight reduction observed following lyophilization.  This 
was to be expected as freezing and drying can result in structural LNP changes leading to 
leakage of the drug during the hydration step (Desai et al. 2002; Yang et al. 2011). 
Despite a small amount of ITE leakage after the freeze and dry process, a high percentage 
of total ITE was retrieved in the final ITE-loaded LNPs using both preparation methods. 
ITE also appeared to be contained within the lipid bilayer, which was supported by 
thermogram analysis and lack of a burst effect in drug release studies. A burst effect, or 
an initial, rapid release of drug within the first thirty minutes, is commonly attributed to 
drug desorption from liposomal surfaces due to weak binding forces between the drug 
and surface lipids. In the present study, ITE release peaked by 24 hours in vitro with no 
burst effect present. This release pattern is in accordance with what has been observed for 
other lipophilic molecules packaged within liposomal nanoparticles (Ramana et al. 2010) 
and supports the likelihood of a steady diffusion of ITE across the lipid bilayer under 
physiological conditions. Importantly, negligible release occurred before analysis, 
suggesting that biological conditions, such as temperature and pH, initiated drug release. 
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Together, the efficient entrapment and steady release of ITE with minimal metabolites 
present suggests that LNPs formulated in the present study could deliver natural ligands 
for continual, more concentrated release within target cells, and thus, more sustained 
AhR activation. 
 AhR activation in DCs has potent immunomodulatory outcomes with 
demonstrated ability to suppress inflammatory diseases (Benson et al. 2012a; Benson and 
Shepherd 2010; Goettel et al. 2016; Quintana et al. 2010a; Yeste et al. 2012). It has been 
reported that non-targeted LNP preferentially interact with antigen presenting cells, 
including DCs and macrophage, and that LNP lipid composition can induce DC 
maturation (Watson et al. 2012, Foged, 2004 #1119). Interestingly, in the present study, 
mature BMDCs exhibited higher LNP density than both immature BMDCs and non-
BMDCs. The LNP formulation did not appear to induce DC maturation as no changes in 
frequencies of mature and immature BMDCs were observed compared to untreated 
controls, suggesting that BMDC maturation state is an important factor in LNP uptake 
efficiency. This outcome was unexpected as immature DCs are highly phagocytic while 
DC maturation corresponds with reduced phagocytic activity (Mellman and Steinman 
2001, Garrett, 2000 #1122), suggesting that phagocytosis is not the primary route for 
LNP uptake by BMDCs. The neutralization of liposomal surface charge by PEGylation 
and the use of phosphatidylcholine, which confers less charge than other phospholipids, 
are highly effective at increasing in vivo stability, but can lead to poor cellular 
interactions (Lee et al. 1993, Watson, 2012 #1111). However, the LNP in this study 
maintained high interaction efficiency with BMDCs. Microscopy and fluorescence 
cytometry confirmed that LNP and BMDCs were directly interacting in a manner 
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suggestive of uptake, and not accumulation on the plasma membrane; however it is 
noteworthy that this study did not definitively establish LNP internalization. To date, 
multiple studies have reported that LNP are internalized by DCs, supporting the 
likelihood of internalization accompanying the DC-LNP interactions observed in the 
present studies (Watson et al. 2012,Soema, 2015 #1112). Interestingly, ITE-loaded LNP 
showed greater cellular interaction than empty LNP, which may be explained by the 
increased LNP rigidity observed following ITE entrapment. Previous reports have shown 
that more rigid LNP are better internalized and result in more potent immune responses 
(Watson et al. 2012, Foged, 2004 #1114). Together, LNP readily interact with BMDCs in 
a maturation dependent manner and ITE-loaded LNP show greater uptake, suggesting 
that AhR agonists will be delivered directly to BMDCs. 
 To further explore the effects of ITE-loaded LNP on DCs, gene transcription was 
evaluated in BMDCs treated with ITE-loaded LNP, empty LNP, and empty LNP with 
ITE-supplemented media compared to TCDD. Both TCDD and ITE-loaded LNP resulted 
in equal induction of the prototypical AhR gene target, CYP1a1, supporting that ITE is 
being delivered and activating the AhR. The lower CYP1a1 induction observed with ITE 
added directly to culture media suggests that ITE-loaded LNP elicit more AhR activity 
than free ITE. This is likely due to LNP enabling higher concentrations of ITE to 
accumulate within cells and/or LNP packaging acting to protect against ITE degradation. 
Strikingly, ITE-loaded LNP were more effective than TCDD in inducing both IDO2 and 
TGFβ3, two genes tightly associated with TCDD-induced tolerogenic DCs (Simones and 
Shepherd 2011, Bankoti, 2010 #683). This suggests that ITE-loaded LNP may provide a 
route for greater induction of an immunoregulatory DC phenotype. Together, 
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immunoregulatory gene expression profiles support that ITE-loaded LNP delivered high 
concentrations of ITE to BMDCs and are potent AhR activators. 
 Nanoparticle composition, size, and surface modifications can alter 
biodistribution and lead to tissue-specific accumulation (Albanese et al. 2012, Love, 1990 
#1115). Thus, LNP were evaluated for murine immune tissue deposition following 
intraperitoneal injection. Interestingly, minimal accumulation was observed in all tissues 
evaluated except the spleen. Substantial accumulation in the spleen was expected with 
intraperitoneal administration of LNP as nanoparticles with hydrodynamic diameters of 
~100nm are associated with splenic deposition and rigid, cholesterol-rich liposomes have 
been shown to preferentially accumulate within the spleen (Capini et al. 2009, Love, 
1990 #1115). Cell-specific uptake was also observed as splenic macrophage and DCs 
showed higher LNP density than T cells or B cells, which was to be expected as APCs 
have been shown to preferentially take up nanoparticles (Liu et al. 2013). This finding 
may also be, in part, due to the organization of splenic tissue, where antigen presenting 
cells are positioned closer to afferent lymphatics than both T cells and B cells, and likely 
provides greater opportunity for LNP interaction with APCs (Calabro et al. 2016). The 
future addition of targeting proteins such as anti-CD11c antibodies, a comprehensive DC 
lineage marker, to the surface of LNP may reduce macrophage uptake and enable greater 
cell specificity in vivo. Together, APCs acquire LNP at higher density than non-APCs 
with preferential splenic accumulation observed following intraperitoneal administration.  
 Seminal work by Yeste et al. (Yeste et al. 2012) has provided promising proof of 
principle for AhR agonist delivery in vivo using gold nanoparticles (auNP). However, key 
concerns have surrounded auNP therapies within the biomedical field (Alkilany and 
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Murphy 2010; Lewinski et al. 2008). At the cellular level, auNP exhibited significant 
cytotoxicity with greater cellular uptake corresponding to increased disruption of 
mitochondrial function, particularly within phagocytes (Liu et al. 2013). Recent studies 
have also identified size and time-dependent toxicity of auNP where substantial 
accumulation and low clearance rates were observed for three months in both the liver 
and spleen (Li et al. 2018). Therefore, alternative, non-toxic nanoparticle carriers are 
more desirable for pharmaceutical use. Additionally, while the present studies used 
nanoparticles loaded with ITE as a proxy for natural AhR agonists, a broad range of 
agonists exist and ligand-dependent effects are well documented (Boule et al. 2018a, 
Ehrlich, 2018 #522, Benson, 2011 #1071). AhR ligands have a common theme of 
hydrophobicity and planarity, suggesting that additional natural agonists could be 
incorporated into the LNP platform similarly to ITE (Pohjanvirta 2011). It is thus highly 
conceivable that this LNP platform could be tailored with ligands that elicit an AhR 
response most efficacious for treatment of specific pathologies. Collectively, the present 
study demonstrates that an alternative non-toxic, biodegradable LNP is an effective 
carrier for AhR agonist delivery and may provide for a more biologically compatible 
delivery system without sacrificing potency of AhR activation.  
  
Conclusion 
 Liposomal nanoparticles exhibit high ITE entrapment efficiency, long-term 
stability, and sustained ITE release under physiological conditions. LNP are 
preferentially acquired by antigen presenting cells both in vivo and in vitro, with mature 
DCs exhibiting greater LNP uptake in vitro. LNP are capable of delivering AhR agonists 
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in order to activate the AhR and yield gene transcription equivalent to or surpassing, the 
prototypical, but highly toxic AHR ligand, TCDD. In conclusion, the agonist-loaded LNP 
developed in this study is a highly promising new route of therapeutic AhR activation. 
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CHAPTER 4: CONCLUSIONS 
 
 Soon after the discovery of the AhR by Conney, Okey, and Nebert, a curious link 
between the AhR and the immune system was identified when rodents exposed to a 
known AhR agonist in vivo displayed severe thymic atrophy.  Since this initial 
observation, AhR-mediated thymic atrophy has been seen in every animal species tested 
to date. Numerous questions surround AhR-mediated thymic atrophy. Specifically, early 
studies showed that AhR activation within the hematopoietic compartment was necessary 
for AhR-mediated atrophy; however, the hematopoietic compartment is highly 
heterogeneous and a key question that has remained since these early studies is whether 
AhR expression within specific cell types of the hematopoietic compartment are 
responsible for thymic atrophy. Additionally, as classes of AhR agonists expand beyond 
exogenous compounds to include endogenous- and dietary-sourced ligands, some of 
which have high therapeutic potential, important questions emerge regarding ligand-
specific effects on the thymus. Therefore, the studies in this dissertation (1) show that 
AhR activation within CD11c+ cells is necessary for TCDD-mediated thymic atrophy, 
and identify ligand-specific effects within the context of thymic atrophy. 
 As our understanding of AhR-mediated immunomodulation expands, the AhR is 
becoming a highly intriguing and promising target for novel therapeutics. Harnessing the 
immunosuppressive potential of AhR activation, particularly within dendritic cells as 
they are high AhR expressers and adopt a tolerogenic phenotype, could lead to regulation 
of inflammation and autoimmune diseases. Proof of principle comes from seminal 
research by the Quintana Laboratory at Harvard that showed systemic ITE exposure 
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could significantly lower disease scores in experimental autoimmune encephalomyelitis 
(EAE), the mouse model of multiple sclerosis. Additionally, ITE loaded onto gold 
nanoparticles in combination with a myelin peptide (MOG35-55) resulted in tolerogenic 
DCs and T cells that significantly reduced the disease pathology. However, the use of 
gold nanoparticles in therapeutic applications is entrenched with concerns regarding 
safety and toxicity. Therefore, the studies in this dissertation (2) develop PEGylated 
liposomal nanoparticles for delivery of AhR agonists, test ITE-loaded liposomal 
nanoparticle interaction and AhR activation in murine bone marrow derived dendritic 
cells, and evaluate liposomal biodistribution in mice. 
 
Thymic atrophy is ligand-specific and TCDD-mediated thymic atrophy requires AhR 
expression in CD11c+ cells. 
 The first goal of this study was to evaluate thymic atrophy by a select panel of 
ligands and determine the role of AhR activation in CD11c+ DCs during TCDD-
mediated thymic atrophy. We demonstrated for the first time that administration of 
endogenous ligand, ITE, p.o. or i.p., resulted in thymic atrophy characteristically similar 
to TCDD albeit at higher doses, as indicated by reduced thymic weight and cellularity 
due to substantial loss of the DP thymocyte population. Conversely, exposure to dietary 
ligand, I3C, had an opposite effect with increased thymic cellularity observed by day 7. 
The effects observed with I3C are quite surprising, and with interest growing in cancer 
biology to promote or augment thymic function following severe immunosuppression 
from chemotherapeutics and radiation, especially in children who do not have such 
expansive T cell repertoires as adults, I3C may hold promise as a natural route to do so 
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(Chung et al. 2014).  
 As the AhR signaling pathway is becoming an increasingly promising clinical 
target with therapeutic immunomodulatory potential, alternatives to TCDD, which is not 
considered suitable for therapeutic applications due to adverse toxicity, are of keen 
interest within the field.  ITE has shown extraordinarily promising therapeutic potential 
in treatment of autoimmune diseases such as experimental autoimmune 
encephalomyelitis (EAE) (Quintana et al. 2010c; Yeste et al. 2012); however, the 
severe thymic atrophy reported here following systemic exposure to ITE is an adverse 
effect that needs to be further considered when evaluating its therapeutic potential. One 
avenue to potentially harness the therapeutic potential of ITE while bypassing this 
adverse effect on the thymus is to contain ITE within a targeted delivery system. The use 
of a delivery system may reduce the dosing regimen, the concentration of systemic ITE 
exposure, and the adverse effects on the thymus. 
 Identification of the key cell type(s) mediating thymic atrophy following AhR 
activation has been an unanswered question in AhR research for multiple decades. While 
seminal work by Staples et al. (1998) showed that AhR activation within the 
hematopoietic compartment is required for TCDD-induced thymic atrophy, work in this 
dissertation has definitively established that AhR expression within CD11c+ cells, a 
comprehensive, but not exclusive, lineage marker for DCs, is necessary for thymic 
atrophy. Complete protection from TCDD-induced atrophy when mice lacked the AhR in 
CD11c+ cells was an unexpected result. DCs in the thymus are a rare population, 
comprising only ~1-2% of cells, while DP thymocytes, the population most affected by 
TCDD, compose ~80% of cells; however, DCs constitutively express high levels of AhR 
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with further inducible expression, while most T cell subsets and developing thymocytes 
are low AhR expressers (Kreitinger et al. 2016). To ensure that CD11c in the thymus is 
exclusive to DCs, we thoroughly performed CD11c staining on non-DC populations, and 
did not detect CD11c expression outside of the DC lineage. We also used a broad panel 
of conditional knock out mice to verify that AhR expression in thymic epithelial cells, 
monocytes and macrophages, as well as thymocytes and mature T cells, did not result in 
protection from thymic atrophy. Together, these results support that DCs are the key cell 
type mediating the rapid, severe loss of thymocytes following exposure to TCDD. It is 
necessary to mention that while CD11c is a comprehensive lineage marker for DCs, and 
it could not be detected on non-DC populations within the thymus, CD11c can be 
expressed by non-DC populations outside of the thymus, such as alveolar macrophages, 
and the studies presented here did not conclusively establish that AhR expression in 
CD11c+ cells specifically located within the thymus are sufficient for thymic atrophy. 
Taken together, to the best of our knowledge, these in vivo studies are the first to identify 
ligand-specific effects on thymic atrophy and to establish a requisite role for AhR 
expression within CD11c+ cells for TCDD-mediated thymic atrophy. 
 
ITE-loaded liposomal nanoparticles for therapeutic AhR activation 
 The second goal of this study was to develop and test a PEGylated liposomal 
nanocarrier for delivery of natural AhR agonists.  We demonstrated that liposomal 
nanoparticles entrap the natural AhR agonist, ITE, within the lipid bilayer with high 
efficiency. While natural AhR agonists provide a promising alternative to the highly toxic 
prototypical ligand, TCDD, substantial barriers currently exist in the rapid metabolism 
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and degradation of natural AhR ligands.  The entrapment of ITE within the lipid bilayer 
resulted in little degradation product and provides a promising form of protection for 
AhR agonists that are less stable than TCDD. Notably, studies presented here 
demonstrate that natural ligands can have adverse consequences similar to TCDD, as ITE 
induced severe thymic atrophy following systemic administration.  This reinforces the 
need for a delivery system that reduces systemic exposure for therapeutic AhR activation, 
but also may suggest that ITE is not the most suitable natural compound. Importantly, the 
platform developed within this study is well suited for incorporation of lipophilic 
compounds and indolic compounds, such as indole-3-carbinol, may be optimal candidates 
given their combination of AhR activating potential and absence of thymic atrophy. Shelf 
life is another factor to consider for clinical utility of novel therapeutics. LNPs within this 
study demonstrated release of ITE under physiological conditions with no leakage of ITE 
being observed under storage conditions and the storage of ITE-loaded LNP for three 
months did not reduce efficacy or interaction with BMDCs. Together, supporting that 
LNP could be highly compatible with pharmaceutical use.   
 TCDD is considered the prototypical AhR ligand for its high binding affinity and 
induction of dioxin-responsive genes, most notably CYP1a1 (Bankoti et al. 2010a; 
Bankoti et al. 2010b; Simones and Shepherd 2011). ITE delivered by LNP were able to 
induce CYP1a1 at the same levels as TCDD, while ITE added directly to culture media 
resulted in lower induction. While the causes for this were not investigated in these 
studies, reasons could include higher ITE concentrations accumulating within BMDCs, 
reduced ITE degradation, or more sustained AhR activation by continual diffusion of ITE 
from LNP. Overall, LNP may circumvent key issues with natural AhR agonists. 
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 In vivo experiments established that LNP accumulated within the spleen. This 
was to be expected given the route of administration and the size of particle, as both 
factors are optimal for splenic accumulation. While APCs of the spleen showed 
preferential LNP interactions, it is important to note that the successful delivery of ITE in 
vivo was not evaluated within these studies. However, in vitro studies indicate that ITE is 
maintained within LNP and then slowly released with a majority of release occurring 
within the first 24 hours, a timeframe that should accommodate LNP trafficking to 
splenic APCs. Notably, LNP of 100nm can accumulate in the liver and the liver is a high 
expresser of both AhR and CYP1a1 (Bozzuto and Molinari 2015; Çağdaş et al. 2014); 
however, LNP trafficking to the liver was not evaluated in the present study. If 
substantial LNP accumulation occurs within the liver, it has the potential to greatly 
reduce LNP efficacy through substantial induction of xenobiotic metabolism. Moreover, 
if a high concentration of ITE is being delivered to the liver, it may result in deleterious 
effects on liver tissue similar to TCDD, such as congestive hepatophathy, or nutmeg 
liver. While this was not evaluated in the present studies, the addition of PEG to LNPs 
has been reported to reduce liver accumulation (Desai et al. 2002) and therefore may 
reduce effects on the liver. 
 
Future directions 
 The AhR provides a promising therapeutic target for treatment of immune-
mediated diseases. Compounds such as ITE have been highlighted as non-toxic 
alternatives to TCDD for therapeutically activating the AhR; however, work here 
suggests that the thymus is adversely affected by systemic ITE exposure. It remains of 
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key interest to further assess the effects of natural ligands, including but not limited to 
ITE and I3C, on the thymus, especially in light of our findings that I3C appeared to have 
an opposite effect on the thymus by increasing, not decreasing, cellularity. While I3C is a 
well-established AhR ligand, we did not evaluate the effects of I3C on the thymus for 
AhR, or CD11c-AhR, dependence. To this end, it is necessary to develop higher 
concentration formulations of lower-affinity agonists, such as ITE and I3C, which would 
enable further testing in mouse strains on the AhRd allele background. Additionally, 
while intraperitoneal injection of ITE-loaded LNP resulted in minimal thymic 
accumulation, the three-day time point of these in vivo LNP exposures is not sufficient to 
gauge thymic atrophy as peak atrophy occurs between 7-10 days post-exposure. Thus, 
future studies with ITE-loaded LNP should consider longer time points for evaluation of 
deleterious effects on the thymus.  
 Sex-dependent effects of AhR activation have been observed throughout my 
doctoral training, are reported in previous publications, and remain of keen interest and 
importance when evaluating AhR activation for therapeutic applications (Benson et al. 
2012a; Nault et al. 2017). Key questions around sex-dependent effects include potential 
differences in AhR expression levels, increased or reduced drug metabolism rates or 
storage, and interactions with non-canonical proteins/pathways. AhR ligands are highly 
lipophilic with bioaccumulation occurring in fatty tissues and non-targeted liposomal 
nanoparticles have also been shown to accumulate within the liver (Lee et al. 2015a). 
Interestingly, in murine livers, females express higher levels of AhR transcripts than 
males; however, this has not yet been evaluated in immune cells or in the thymus. 
Notably, hepatic transcriptomic studies in rodents show that TCDD exposure results in 
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greater transcriptional variation in AhR-related genes within livers of males than females 
(Lee et al. 2015a). The authors of this report suggest that the narrowed response in 
females may be an adaptive function that enables females to better handle toxic 
metabolites and to limit adverse toxicity. Interestingly, male rodents show increased 
transcripts involved in oxidative stress and fatty acid biosynthesis after AhR activation. 
This could conceivably impact the efficacy and adverse side effects of LNP-delivered 
ligands in a sex-dependent manner; however, these possibilities remain to be evaluated. 
Taken together, AhR immune responsiveness and toxicity differ between male and 
female animals, which reinforces the importance of controlling for sex differences in both 
mechanistic and therapeutic AhR studies. 
 Collectively this work provides novel discoveries that contribute significantly to 
further our understanding of how the Aryl hydrocarbon receptor signaling pathway 
regulates the immune system. The data presented in this dissertation provide the 
foundation to direct future research studies that are expected to advance the basic, 
biological function of the AhR in the immune system, while also promoting the exciting 
potential of AhR ligand-loaded liposomal nanoparticles to become highly effective 
therapeutics for the treatment of immune-mediated diseases. 
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